<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vitamin D supplementation for chronic liver diseases in adults - Bjelakovic, M - 2021 | Cochrane Library</title> <meta content="Vitamin D supplementation for chronic liver diseases in adults - Bjelakovic, M - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011564.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vitamin D supplementation for chronic liver diseases in adults - Bjelakovic, M - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011564.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011564.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Vitamin D supplementation for chronic liver diseases in adults" name="citation_title"/> <meta content="Milica Bjelakovic" name="citation_author"/> <meta content="Clinical Centre Nis" name="citation_author_institution"/> <meta content="Dimitrinka Nikolova" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet" name="citation_author_institution"/> <meta content="Goran Bjelakovic" name="citation_author"/> <meta content="Medical Faculty, University of Nis" name="citation_author_institution"/> <meta content="goranb@junis.ni.ac.rs" name="citation_author_email"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD011564.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/08/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011564.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011564.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011564.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Dietary Supplements; *Hepatitis C, Chronic; Quality of Life; Vitamin D" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011564.pub3&amp;doi=10.1002/14651858.CD011564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011564\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011564\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","pt","ms","hr","fr","zh_HANS","zh_HANT","th","ja","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011564.pub3",title:"Vitamin D supplementation for chronic liver diseases in adults",firstPublishedDate:"Aug 25, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato-Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011564.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011564.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011564.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011564.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011564.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011564.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011564.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011564.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011564.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011564.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5232 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011564.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-sec-0117"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/appendices#CD011564-sec-0122"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/table_n/CD011564StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/table_n/CD011564StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vitamin D supplementation for chronic liver diseases in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/information#CD011564-cr-0004">Milica Bjelakovic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/information#CD011564-cr-0005">Dimitrinka Nikolova</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/information#CD011564-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Goran Bjelakovic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011564.pub3/information#CD011564-cr-0007">Christian Gluud</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/information/en#CD011564-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 August 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011564.pub3">https://doi.org/10.1002/14651858.CD011564.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011564-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011564-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011564-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011564-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011564-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011564-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD011564-abs-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011564-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011564-abs-0001" lang="en"> <section id="CD011564-sec-0001"> <h3 class="title" id="CD011564-sec-0001">Background</h3> <p>Vitamin D deficiency is often reported in people with chronic liver diseases. Improving vitamin D status could therefore be beneficial for people with chronic liver diseases. </p> </section> <section id="CD011564-sec-0002"> <h3 class="title" id="CD011564-sec-0002">Objectives</h3> <p>To assess the beneficial and harmful effects of vitamin D supplementation in adults with chronic liver diseases. </p> </section> <section id="CD011564-sec-0003"> <h3 class="title" id="CD011564-sec-0003">Search methods</h3> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE Ovid, Embase Ovid, LILACS, Science Citation Index Expanded, and Conference Proceedings Citation Index‐Science. We also searched ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform. We scanned bibliographies of relevant publications and enquired experts and pharmaceutical companies as to additional trials. All searches were up to November 2020. </p> </section> <section id="CD011564-sec-0004"> <h3 class="title" id="CD011564-sec-0004">Selection criteria</h3> <p>Randomised clinical trials that compared vitamin D at any dose, duration, and route of administration versus placebo or no intervention in adults with chronic liver diseases. Vitamin D could have been administered as supplemental vitamin D (vitamin D<sub>3</sub> (cholecalciferol) or vitamin D<sub>2</sub> (ergocalciferol)), or an active form of vitamin D (1α‐hydroxyvitamin D (alfacalcidol), 25‐hydroxyvitamin D (calcidiol), or 1,25‐dihydroxyvitamin D (calcitriol)). </p> </section> <section id="CD011564-sec-0005"> <h3 class="title" id="CD011564-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. We used GRADE to assess the certainty of evidence. </p> </section> <section id="CD011564-sec-0006"> <h3 class="title" id="CD011564-sec-0006">Main results</h3> <p>We included 27 randomised clinical trials with 1979 adult participants. This review update added 12 trials with 945 participants. We assessed all trials at high risk of bias. All trials had a parallel‐group design. Eleven trials were conducted in high‐income countries and 16 trials in middle‐income countries. Ten trials included participants with chronic hepatitis C, five trials participants with liver cirrhosis, 11 trials participants with non‐alcoholic fatty liver disease, and one trial liver transplant recipients. All of the included trials reported the baseline vitamin D status of participants. Participants in nine trials had baseline serum 25‐hydroxyvitamin D levels at or above vitamin D adequacy (20 ng/mL), whilst participants in the remaining 18 trials were vitamin D insufficient (less than 20 ng/mL). Twenty‐four trials administered vitamin D orally, two trials intramuscularly, and one trial intramuscularly and orally. In all 27 trials, the mean duration of vitamin D supplementation was 6 months, and the mean follow‐up of participants from randomisation was 7 months. Twenty trials (1592 participants; 44% women; mean age 48 years) tested vitamin D<sub>3</sub> (cholecalciferol); three trials (156 participants; 28% women; mean age 54 years) tested vitamin D<sub>2</sub>; four trials (291 participants; 60% women; mean age 52 years) tested 1,25‐dihydroxyvitamin D; and one trial (18 participants; 0% women; mean age 52 years) tested 25‐hydroxyvitamin D. One trial did not report the form of vitamin D. Twelve trials used a placebo, whilst the other 15 trials used no intervention in the control group. Fourteen trials appeared to be free of vested interest. Eleven trials did not provide any information on clinical trial support or sponsorship. Two trials were funded by industry. </p> <p>We are very uncertain regarding the effect of vitamin D versus placebo or no intervention on all‐cause mortality (risk ratio (RR) 0.86, 95% confidence interval (CI) 0.51 to 1.45; 27 trials; 1979 participants). The mean follow‐up was 7 months (range 1 to 18 months). We are very uncertain regarding the effect of vitamin D versus placebo or no intervention on liver‐related mortality (RR 1.62, 95% CI 0.08 to 34.66; 1 trial; 18 participants) (follow‐up: 12 months); serious adverse events such as hypercalcaemia (RR 5.00, 95% CI 0.25 to 100.8; 1 trial; 76 participants); myocardial infarction (RR 0.75, 95% CI 0.08 to 6.81; 2 trials; 86 participants); thyroiditis (RR 0.33, 95% CI 0.01 to 7.91; 1 trial; 68 participants); circular haemorrhoidal prolapse (RR 3.00, 95% CI 0.14 to 65.9; 1 trial; 20 participants); bronchopneumonia (RR 0.33, 95% CI 0.02 to 7.32; 1 trial 20 participants); and non‐serious adverse events. The certainty of evidence for all outcomes is very low. </p> <p>We found no data on liver‐related morbidity such as gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, ascites, or liver cancer. There were also no data on health‐related quality of life. </p> <p>The evidence is also very uncertain regarding the effect of vitamin D versus placebo or no intervention on rapid, early, and sustained virological response in people with chronic hepatitis C. </p> </section> <section id="CD011564-sec-0007"> <h3 class="title" id="CD011564-sec-0007">Authors' conclusions</h3> <p>Given the high risk of bias and insufficient power of the included trials and the very low certainty of the available evidence, vitamin D supplementation versus placebo or no intervention may increase or reduce all‐cause mortality, liver‐related mortality, serious adverse events, or non‐serious adverse events in adults with chronic liver diseases. There is a lack of data on liver‐related morbidity and health‐related quality of life. Further evidence on clinically important outcomes analysed in this review is needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011564-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011564-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011564-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011564-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011564-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011564-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011564-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011564-abs-0018">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011564-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011564-abs-0021">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011564-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011564-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD011564-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011564-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011564-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011564-abs-0002" lang="en"> <h3>Vitamin D supplementation for chronic liver diseases</h3> <p><b>Review question</b> </p> <p>Is vitamin D supplementation beneficial or harmful for adults with chronic liver diseases?</p> <p><b>Background</b> </p> <p>The available evidence on vitamin D and chronic liver diseases in adults is inconclusive. The aim of this systematic review (a summary of results of available healthcare trials) was to analyse the benefits and harms of the different forms of vitamin D in people with chronic liver diseases. </p> <p><b>Study characteristics</b> </p> <p>Twenty‐seven trials with 1979 adult participants provided data for this review. This review update added 12 trials with 945 participants. The 1979 trial participants were randomly assigned to vitamin D compared with placebo (dummy pill) or no treatment. Eleven trials were conducted in high‐income countries, and 16 trials in middle‐income countries. The age range of the participants was 28 years to 61 years, and on average 44% were women. Ten trials included people with chronic hepatitis C, five trials people with liver cirrhosis, 11 trials people with non‐alcoholic fatty liver disease, and one trial liver transplant recipients. There were no trials including people with chronic hepatitis B or inherited liver diseases. All of the included trials reported the baseline vitamin D status of participants. Vitamin D administration lasted on average six months, and most trials used the cholecalciferol (vitamin D<sub>3</sub>) form. </p> <p><b>Funding</b> </p> <p>Fourteen trials appeared to be free of vested interest that could bias the trial results. Eleven trials may not have been free of vested interest, as they did not provide any information on clinical trial support or sponsorship. Two trials were funded by industry. We found no difference between trials without industry support compared to trials at risk of industry support in our analysis. </p> <p><b>Key results</b> </p> <p>There is not enough evidence to determine whether vitamin D has beneficial or harmful effects, or has little to no effect on chronic liver diseases in adults. There were too few participants in the individual trials as well as in our evidence synthesis. The trials were at high risk of bias so we lack fair assessments of the benefits and harms of vitamin D in this population. Neither benefits nor harms of vitamin D supplementation in people with chronic liver diseases can be excluded. There were no trials including people with chronic hepatitis B and inherited liver diseases. </p> <p><b>Quality of the evidence</b> </p> <p>We judged all trials to be at high risk of bias (that is an underestimation or overestimation of the true intervention effect). The certainty of evidence is very low. </p> <p><b>Currentness of evidence</b> </p> <p>The evidence is current to November 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011564-sec-0117" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011564-sec-0117"></div> <h3 class="title" id="CD011564-sec-0118">Implications for practice</h3> <section id="CD011564-sec-0118"> <p>Based on trials with very low certainty of evidence, vitamin D supplementation versus placebo or no intervention may increase or reduce all‐cause mortality, liver‐related mortality, serious adverse events, and non‐serious adverse events in adults with chronic liver diseases. Evidence on the effect of vitamin D supplementation on liver‐related morbidity such as gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, ascites, or liver cancer, and on health‐related quality of life is lacking. Our conclusions are based on trials at high risk of bias, with an insufficient number of participants, and on a lack of trial data on clinically important outcomes. In addition, the analysed trials showed significant intertrial heterogeneity for some outcomes. </p> </section> <h3 class="title" id="CD011564-sec-0119">Implications for research</h3> <section id="CD011564-sec-0119"> <p>More evidence is needed before any final conclusions can be drawn on the effect of vitamin D on chronic liver diseases, especially in people with cholestatic and autoimmune liver diseases. There is also a need for trials evaluating vitamin D supplementation versus placebo or no intervention in people with chronic hepatitis C, chronic hepatitis B, and autoimmune liver diseases. More randomised clinical trials assessing a longer duration of vitamin D intervention and different forms of vitamin D with a greater number of participants, assessing clinical outcomes, seem appropriate. The effect of vitamin D on health‐related quality of life also deserves further investigation. Future trials should be designed according to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement (<a href="http://www.spirit-statement.org/" target="_blank">www.spirit-statement.org/</a>) and reported according to the CONSORT statement (<a href="http://www.consort-statement.org" target="_blank">www.consort-statement.org</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011564-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011564-sec-0008"></div> <div class="table" id="CD011564-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vitamin D compared with placebo or no intervention for chronic liver diseases in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vitamin D compared with placebo or no intervention for chronic liver diseases in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic liver diseases<br/><b>Setting:</b> in‐ and outpatients<br/><b>Intervention:</b> vitamin D<br/><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vitamin D</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Follow‐up: mean 7 months (1 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.51 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1979<br/>(27 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/>(11 to 30) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Liver‐related mortality</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.62<br/>(0.08 to 34.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>18<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No information was available to calculate absolute effects.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> <p>Follow‐up: mean 10.5 months (6 to 12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Several serious adverse events were reported: hypercalcaemia (RR 5.00, 95% CI 0.25 to 100.8; 1 trial; 76 participants); myocardial infarction (RR 0.75, 95% CI 0.08 to 6.81; 2 trials; 86 participants); thyroiditis (RR 0.33, 95% CI 0.01 to 7.91; 1 trial; 68 participants); circular haemorrhoidal prolapse (RR 3.00, 95% CI 0.14 to 65.9; 1 trial; 20 participants); bronchopneumonia (RR 0.33, 95% CI 0.02 to 7.32; 1 trial; 20 participants). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Liver‐related morbidity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Health‐related quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐serious adverse events</p> <p>Follow‐up: mean 7 months (3 to 12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 trial reported 1 single non‐serious adverse event, and another trial reported 16 single non‐serious adverse events, for a total of 17 types of non‐serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure of sustained virological response</p> <p>Follow‐up: mean 16 months (6 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.65<br/>(0.42 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>630<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>484 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>315 per 1000<br/>(203 to 489) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded because of risk of bias (1 level) (all trials were at high risk of bias); and imprecision (2 levels) (few events, and the optimal information size of 63,116 participants (based on a proportion of 2% in the control group, a relative risk reduction of 20%, an alpha of 1.25%, and a beta of 10%) was not met; wide CI which included both benefits and harms).<br/><sup>2</sup>Downgraded because of risk of bias (1 level) (the trial was at high risk of bias); and imprecision (2 levels) (very few events, and wide CI which included both benefits and harms).<br/><sup>3</sup>Downgraded because of risk of bias (1 level) (all trials were at high risk of bias); and imprecision (2 levels) (very few events, and wide CI which included both benefits and harms).<br/><sup>4</sup>Downgraded because of risk of bias (1 level) (all trials were at high risk of bias); imprecision (2 levels) (the optimal information size of 7570 participants (based on a proportion of 48% in the control group, a relative risk reduction of 20%, an alpha of 1.25%, and a beta of 10%) was not met); inconsistency (1 level) (considerable heterogeneity); and indirectness (3 levels)(sustained virological response is a surrogate outcome). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011564-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011564-sec-0009"></div> <p>Vitamin D is either synthesised in the skin (vitamin D<sub>3</sub> (cholecalciferol)) or is obtained from dietary sources (vitamin D<sub>3</sub> or vitamin D<sub>2</sub> (ergocalciferol)). Vitamin D<sub>3</sub> and D<sub>2</sub> do not have biological activity. Both forms are metabolised in the liver to 25‐hydroxyvitamin D (calcidiol) and in the kidneys to the biologically active form known as 1,25‐dihydroxyvitamin D (calcitriol), which functions as a steroid‐like hormone (<a href="./references#CD011564-bbs2-0214" title="Wesley PikeJ , ShevdeNK . The vitamin D receptor. In: FeldmanD , Wesley PikeJ , GlorieuxFH , editors(s). Vitamin D. 2nd edition. Amsterdam: Elsevier Academic Press, 2005:167-91.">Wesley Pike 2005</a>). The effects of 1,25‐dihydroxyvitamin D are mediated by its binding to vitamin D receptors in the cells (<a href="./references#CD011564-bbs2-0214" title="Wesley PikeJ , ShevdeNK . The vitamin D receptor. In: FeldmanD , Wesley PikeJ , GlorieuxFH , editors(s). Vitamin D. 2nd edition. Amsterdam: Elsevier Academic Press, 2005:167-91.">Wesley Pike 2005</a>). Renal production of 1,25‐dihydroxyvitamin D is regulated by parathyroid hormone levels, by serum calcium and phosphorus levels, and by the phosphaturic hormone fibroblast growth factor‐23 (<a href="./references#CD011564-bbs2-0149" title="Kovesdy CsabaP , QuarlesLD . Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrology Dialysis Transplantation2013;28(9):2228-36.">Kovesdy 2013</a>). </p> <section id="CD011564-sec-0010"> <h3 class="title" id="CD011564-sec-0010">Description of the condition</h3> <p>Vitamin D status is determined by the measurement of the serum 25‐hydroxyvitamin D level (<a href="./references#CD011564-bbs2-0156" title="LipsP . Which circulating level of 25-hydroxyvitamin D is appropriate. Journal of Steroid Biochemistry and Molecular Biology2004;89-90(1-5):611-4.">Lips 2004</a>; <a href="./references#CD011564-bbs2-0081" title="Dawson-HughesB , HeaneyRP , HolickMF , LipsP , MeunierPJ , ViethR . Estimates of optimal vitamin D status. Osteoporosis International2005;16(7):713-6.">Dawson‐Hughes 2005</a>; <a href="./references#CD011564-bbs2-0059" title="Bischoff-FerrariH . Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary. Best Practice &amp; Research. Clinical Rheumatology2009;23(6):789-95.">Bischoff‐Ferrari 2009</a>). A number of methods are used to measure vitamin D status (radioimmunoassay; high‐performance/pressure liquid chromatography (HPLC); liquid chromatography‐tandem mass spectrometry (LC‐MS/MS); and more recently chemiluminescent immunoassay (CLIA)) (<a href="./references#CD011564-bbs2-0053" title="AtefSH . Vitamin D assays in clinical laboratory: past, present and future challenges. Journal of Steroid Biochemistry and Molecular Biology2018;175:136-7.">Atef 2018</a>). The accuracy of these methods varies significantly. HPLC and LC‐MS/MS can measure vitamin D<sub>2</sub> and D<sub>3</sub> independently and are considered as the gold standard (<a href="./references#CD011564-bbs2-0132" title="HollisBW . Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. American Journal of Clinical Nutrition2008;88(2):507S-10S.">Hollis 2008</a>). </p> <p>Optimal sun exposure and dietary intake are related to optimal vitamin D status. The US Institute of Medicine recommended target serum 25‐hydroxyvitamin D levels of 20 ng/mL (50 nmol/L) (<a href="./references#CD011564-bbs2-0136" title="Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press, 2011.">IOM 2011</a>). Based on the systematic review prepared by the US Institute of Medicine, there are insufficient data to determine the safe upper limit of serum 25‐hydroxyvitamin D levels (<a href="./references#CD011564-bbs2-0136" title="Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press, 2011.">IOM 2011</a>). However, serum 25‐hydroxyvitamin D concentrations above 50 ng/mL (125 nmol/L) are considered potentially harmful (<a href="./references#CD011564-bbs2-0136" title="Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press, 2011.">IOM 2011</a>). The International Osteoporosis Foundation and the Endocrine Society Task Force recommend a target serum 25‐hydroxyvitamin D level of 30 ng/mL (75 nmol/L) (<a href="./references#CD011564-bbs2-0082" title="Dawson-HughesB , MithalA , BonjourJP , BoonenS , BurckhardtP , FuleihanGE , et al. IOF position statement: vitamin D recommendations for older adults. Osteoporosis International2010;21(7):1151-4.">Dawson‐Hughes 2010</a>; <a href="./references#CD011564-bbs2-0130" title="HolickMF , BinkleyNC , Bischoff-FerrariHA , GordonCM , HanleyDA , HeaneyRP , et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology2011;96(7):1911-30.">Holick 2011</a>). </p> <p>The worldwide prevalence of suboptimal vitamin D status is estimated to be high (<a href="./references#CD011564-bbs2-0158" title="LipsP . Worldwide status of vitamin D nutrition. Journal of Steroid Biochemistry and Molecular Biology2010;121(1-2):297-300.">Lips 2010</a>; <a href="./references#CD011564-bbs2-0210" title="Van SchoorNM , LipsP . Worldwide vitamin D status. Best Practice &amp; Research. Clinical Endocrinology &amp; Metabolism2011;25(4):671-80.">Van Schoor 2011</a>; <a href="./references#CD011564-bbs2-0127" title="HilgerJ , FriedelA , HerrR , RauschT , RoosF , WahlDA , et al. A systematic review of vitamin D status in populations worldwide. British Journal of Nutrition2014;111(1):23-45.">Hilger 2014</a>). The major causes of vitamin D deficiency are insufficient exposure to sunlight, decreased dietary intake, skin pigmentation, obesity, and advanced age (<a href="./references#CD011564-bbs2-0157" title="LipsP . Vitamin D physiology. Progress in Biophysics and Molecular Biology2006;92(1):4-8.">Lips 2006</a>; <a href="./references#CD011564-bbs2-0129" title="HolickMF . Vitamin D deficiency. New England Journal of Medicine2007;357(3):266-81.">Holick 2007</a>; <a href="./references#CD011564-bbs2-0208" title="TsiarasWG , WeinstockMA . Factors influencing vitamin D status. Acta Dermato-Venereologica2011;91(2):115-24.">Tsiaras 2011</a>; <a href="./references#CD011564-bbs2-0181" title="Public Health England. SACN vitamin D and health report. www.gov.uk/government/publications/sacn-vitamin-d-and-health-report (accessed 17 July 2017).">SACN 2016</a>). One systematic review of prospective and intervention studies that assessed the effect of vitamin D status on non‐skeletal outcomes suggested that low vitamin D status in a wide spectrum of diseases may be a marker of ill health (<a href="./references#CD011564-bbs2-0054" title="AutierP , BoniolM , MullieP . Vitamin D status and ill health: a systematic review. Lancet Diabetes &amp; Endocrinology2014;2(1):76-89.">Autier 2014</a>). </p> <p>Vitamin D undergoes important biotransformation in the liver. The liver also plays a critical role in the inactivation of vitamin D. Because vitamin D is metabolised by the liver, abnormal vitamin D metabolism might be expected to be associated with chronic liver diseases. Vitamin D deficiency has been frequently reported in people with chronic liver diseases (<a href="./references#CD011564-bbs2-0052" title="ArtehJ , NarraS , NairS . Prevalence of vitamin D deficiency in chronic liver disease. Digestive Diseases and Sciences2010;55(9):2624-8.">Arteh 2010</a>; <a href="./references#CD011564-bbs2-0166" title="MalhamM , JørgensenSP , OttP , AgnholtJ , VilstrupH , BorreM , et al. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World Journal of Gastroenterology2011;17(7):922-5.">Malham 2011</a>; <a href="./references#CD011564-bbs2-0145" title="KitsonMT , RobertsSK . D-livering the message: the importance of vitamin D status in chronic liver disease. Journal of Hepatology2012;57(4):897-909.">Kitson 2012</a>; <a href="./references#CD011564-bbs2-0155" title="LimLY , ChalasaniN . Vitamin D deficiency in patients with chronic liver disease and cirrhosis. Current Gastroenterology Reports2012;14(1):67-73.">Lim 2012</a>; <a href="./references#CD011564-bbs2-0198" title="StokesCS , VolmerDA , GrünhageF , LammertF . Vitamin D in chronic liver disease. Liver International2013;33(3):338-52.">Stokes 2013</a>; <a href="./references#CD011564-bbs2-0195" title="SkaabyT , HusemoenLL , BorglykkeA , JørgensenT , ThuesenBH , PisingerC , et al. Vitamin D status, liver enzymes, and incident liver disease and mortality: a general population study. Endocrine2014;47(1):213-20.">Skaaby 2014</a>). There is evidence that low vitamin D status is associated with increased mortality in chronic liver diseases (<a href="./references#CD011564-bbs2-0178" title="Putz-BankutiC , PilzS , StojakovicT , ScharnaglH , PieberTR , TraunerM , et al. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver International2012;32(5):845-51.">Putz‐Bankuti 2012</a>; <a href="./references#CD011564-bbs2-0212" title="WangJB , AbnetCC , ChenW , DawseySM , FanJH , YinLY , et al. Association between serum 25(OH) vitamin D, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. British Journal of Cancer2013;109(7):1997-2004.">Wang 2013</a>; <a href="./references#CD011564-bbs2-0199" title="StokesCS , KrawczykM , ReichelC , LammertF , GrünhageF . Vitamin D deficiency is associated with mortality in patients with advanced liver cirrhosis. European Journal of Clinical Investigation2014;44(2):176-83.">Stokes 2014</a>; <a href="./references#CD011564-bbs2-0092" title="FinkelmeierF , KronenbergerB , ZeuzemS , PiiperA , WaidmannO . Low 25-hydroxyvitamin D levels are associated with infections and mortality in patients with cirrhosis. PLOS ONE2015;10(6):e0132119.">Finkelmeier 2015</a>; <a href="./references#CD011564-bbs2-0175" title="PaternostroR , WagnerD , ReibergerT , MandorferM , SchwarzerR , FerlitschM , et al. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. Wiener Klinische Wochenschrift2017;129(1-2):8-15.">Paternostro 2017</a>). </p> </section> <section id="CD011564-sec-0011"> <h3 class="title" id="CD011564-sec-0011">Description of the intervention</h3> <p>Vitamin D can be administered as supplemental vitamin D (vitamin D<sub>3</sub> (cholecalciferol) or vitamin D<sub>2</sub> (ergocalciferol)) or as an active form of vitamin D (1α‐hydroxyvitamin D (alfacalcidol), 25‐hydroxyvitamin D (calcidiol), or 1,25‐dihydroxyvitamin D (calcitriol)). Vitamin D supplementation prevents osteoporosis and osteomalacia (<a href="./references#CD011564-bbs2-0157" title="LipsP . Vitamin D physiology. Progress in Biophysics and Molecular Biology2006;92(1):4-8.">Lips 2006</a>). It is speculated that vitamin D supplementation may confer benefits beyond the skeletal system, including chronic liver diseases (<a href="./references#CD011564-bbs2-0080" title='DavisCD , DwyerJT . The "sunshine vitamin": benefits beyond bone?Journal of the National Cancer Institute2007;99(21):1563-5.'>Davis 2007</a>; <a href="./references#CD011564-bbs2-0145" title="KitsonMT , RobertsSK . D-livering the message: the importance of vitamin D status in chronic liver disease. Journal of Hepatology2012;57(4):897-909.">Kitson 2012</a>; <a href="./references#CD011564-bbs2-0120" title="HanYP , KongM , ZhengS , RenY , ZhuL , ShiH , et al. Vitamin D in liver diseases: from mechanisms to clinical trials. Journal of Gastroenterology and Hepatology2013;28(Suppl 1):49-55.">Han 2013</a>; <a href="./references#CD011564-bbs2-0087" title="ElangovanH , ChahalS , GuntonJE . Vitamin D in liver disease: current evidence and potential directions. Biochimica et Biophysica Acta2017;1863(4):907-16.">Elangovan 2017</a>). </p> </section> <section id="CD011564-sec-0012"> <h3 class="title" id="CD011564-sec-0012">How the intervention might work</h3> <p>Vitamin D supplementation may have beneficial effects on bone disorders in people with chronic liver diseases (<a href="./references#CD011564-bbs2-0104" title="GuañabensN , ParésA . Liver and bone. Archives of Biochemistry and Biophysics2010;503(1):84-94.">Guañabens 2010</a>; <a href="./references#CD011564-bbs2-0164" title="LuxonBA . Bone disorders in chronic liver diseases. Current Gastroenterology Reports2011;13(1):40-8.">Luxon 2011</a>). Vitamin D supplementation has also been suggested as a potential therapeutic in people with chronic hepatitis B infection (<a href="./references#CD011564-bbs2-0090" title="FarnikH , BojungaJ , BergerA , AllwinnR , WaidmannO , KronenbergerB , et al. Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology (Baltimore, Md.)2013;58(4):1270-6.">Farnik 2013</a>; <a href="./references#CD011564-bbs2-0165" title="MahamidM , NseirW , Abu ElhijaO , ShteingartS , MahamidA , SmamraM , et al. Normal vitamin D levels are associated with spontaneous hepatitis B surface antigen seroclearance. World Journal of Gastroenterology2013;5(6):328-31.">Mahamid 2013</a>); chronic hepatitis C infection (<a href="./references#CD011564-bbs2-0177" title="PettaS , CammàC , ScazzoneC , TripodoC , Di MarcoV , BonoA , et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology (Baltimore, Md.)2010;51(4):1158-67.">Petta 2010</a>; <a href="./references#CD011564-bbs2-0106" title="GutierrezJA , ParikhN , BranchAD . Classical and emerging roles of vitamin D in hepatitis C virus infection. Seminars in Liver Disease2011;31(4):387-98.">Gutierrez 2011</a>; <a href="./references#CD011564-bbs2-0062" title="BitettoD , FabrisC , FornasiereE , PipanC , FumoloE , CussighA , et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transplant International2012;24(1):43-50.">Bitetto 2012</a>; <a href="./references#CD011564-bbs2-0072" title="CacopardoB , CammaC , PettaS , PinzoneMR , CappellaniA , ZanghiA , et al. Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. Frontiers in Bioscience (Elite Edition)2012;4:1276-86.">Cacopardo 2012</a>; <a href="./references#CD011564-bbs2-0077" title="CholongitasE , TheocharidouE , GoulisJ , TsochatzisE , AkriviadisE , BurroughsK . Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection. Alimentary Pharmacology &amp; Therapeutics2012;35(6):634-46.">Cholongitas 2012</a>; <a href="./references#CD011564-bbs2-0161" title="LuongKV , NguyenLT . Theoretical basis of a beneficial role for vitamin D in viral hepatitis. World Journal of Gastroenterology2012;18(38):5338-50.">Luong 2012</a>); autoimmune hepatitis (<a href="./references#CD011564-bbs2-0162" title="LuongKV , NguyenLT . The role of vitamin D in autoimmune hepatitis. Journal of Clinical Medicine Research2013;5(6):407-15.">Luong 2013a</a>); non‐alcoholic fatty liver disease (<a href="./references#CD011564-bbs2-0097" title="GeierA . Shedding new light on vitamin D and fatty liver disease. Journal of Hepatology2011;55(2):273-5.">Geier 2011</a>; <a href="./references#CD011564-bbs2-0088" title="EliadesM , SpyrouE , AgrawalN , LazoM , BrancatiFL , PotterJJ , et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Alimentary Pharmacology &amp; Therapeutics2013;38(3):246-54.">Eliades 2013</a>; <a href="./references#CD011564-bbs2-0151" title="KwokRM , TorresDM , HarrisonSA . Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association. Hepatology (Baltimore, Md.)2013;58(3):1166-74.">Kwok 2013</a>; <a href="./references#CD011564-bbs2-0089" title="EliadesM , SpyrouE . Vitamin D: a new player in non-alcoholic fatty liver disease. World Journal of Gastroenterology2015;21(6):1718-27.">Eliades 2015</a>); primary biliary cirrhosis (<a href="./references#CD011564-bbs2-0154" title="LiYJ , TangYW , ShiYQ , HanS , WangJB , ZhouXM , et al. Polymorphisms in the vitamin D receptor gene and risk of primary biliary cirrhosis: a meta-analysis. Journal of Gastroenterology and Hepatology2013;29(4):706-15.">Li 2013</a>; <a href="./references#CD011564-bbs2-0163" title="LuongKV , NguyenLT . The role of vitamin D in primary biliary cirrhosis: possible genetic and cell signaling mechanisms. Gastroenterology Research and Practice2013;2013:602321.">Luong 2013b</a>); alcoholic cirrhosis (<a href="./references#CD011564-bbs2-0206" title="TrépoE , OuzielR , PradatP , MomozawaY , QuertinmontE , GervyC , et al. Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. Journal of Hepatology2013;59(2):344-50.">Trépo 2013</a>; <a href="./references#CD011564-bbs2-0148" title="KonstantakisC , TselekouniP , KalafateliM , TriantosC . Vitamin D deficiency in patients with liver cirrhosis. Annals of Gastroenterology2016;29(3):297-306.">Konstantakis 2016</a>); and hepatocellular carcinoma (<a href="./references#CD011564-bbs2-0076" title="ChiangKC , YehCN , ChenMF , ChenTC . Hepatocellular carcinoma and vitamin D: a review. Journal of Gastroenterology and Hepatology2011;26(11):1597-603.">Chiang 2011</a>; <a href="./references#CD011564-bbs2-0152" title="LangeCM , MikiD , OchiH , NischalkeHD , BojungaJ , BibertS , et al. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLOS ONE2013;8(5):e64053.">Lange 2013</a>). It is currently unclear how vitamin D exerts its postulated beneficial effects apart from possibly correcting vitamin D serum levels to something seemingly more normal (<a href="./references#CD011564-bbs2-0222" title="ZittermannA , ErnstJB , GummertJF , BörgermannJ . Vitamin D supplementation, body weight and human serum 25-hydroxyvitamin D response: a systematic review. European Journal of Nutrition2014;53(2):367-74.">Zittermann 2014</a>). </p> </section> <section id="CD011564-sec-0013"> <h3 class="title" id="CD011564-sec-0013">Why it is important to do this review</h3> <p>Observational studies reported a high prevalence of vitamin D insufficiency across a spectrum of chronic liver diseases (<a href="./references#CD011564-bbs2-0052" title="ArtehJ , NarraS , NairS . Prevalence of vitamin D deficiency in chronic liver disease. Digestive Diseases and Sciences2010;55(9):2624-8.">Arteh 2010</a>; <a href="./references#CD011564-bbs2-0155" title="LimLY , ChalasaniN . Vitamin D deficiency in patients with chronic liver disease and cirrhosis. Current Gastroenterology Reports2012;14(1):67-73.">Lim 2012</a>; <a href="./references#CD011564-bbs2-0120" title="HanYP , KongM , ZhengS , RenY , ZhuL , ShiH , et al. Vitamin D in liver diseases: from mechanisms to clinical trials. Journal of Gastroenterology and Hepatology2013;28(Suppl 1):49-55.">Han 2013</a>; <a href="./references#CD011564-bbs2-0091" title="FinkelmeierF , KronenbergerB , KöberleV , BojungaJ , ZeuzemS , TrojanJ , et al. Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study. Alimentary Pharmacology &amp; Therapeutics2014;39(10):1204-12.">Finkelmeier 2014</a>). However, the available evidence on the benefits and harms of vitamin D supplementation in people with chronic liver diseases is insufficient and inconsistent. Meta‐analyses of observational studies and interventional trials in people with chronic hepatitis B or C virus infection and non‐alcoholic fatty liver disease found contradictory results (<a href="./references#CD011564-bbs2-0211" title="VillarLM , Del CampoJA , RanchalI , LampeE , Romero-GomezM . Association between vitamin D and hepatitis C virus infection: a meta-analysis. World Journal of Gastroenterology2013;19(35):5917-24.">Villar 2013</a>; <a href="./references#CD011564-bbs2-0146" title="KitsonMT , SarrazinC , ToniuttoP , EslickGD , RobertsSK . Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. Journal of Hepatology2014;61(6):1247-52.">Kitson 2014</a>: <a href="./references#CD011564-bbs2-0171" title="Mosannen MozaffariH , AbbasiHA , GoshayeshiG , EsmaeelzadehA , BahariA , MokhtarifarA , et al. Effect of vitamin D supplementation on chronic liver disease: systematic literature review. Reviews in Clinical Medicine2017;4(1):14-9.">Mosannen 2017</a>; <a href="./references#CD011564-bbs2-0202" title="TabriziR , MoosazadehM , LankaraniKB , AkbariM , HeydariST , KolahdoozF , et al. The effects of vitamin D supplementation on metabolic profiles and liver function in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Diabetes &amp; Metabolic Syndrome2017;11:S975-82.">Tabrizi 2017</a>; <a href="./references#CD011564-bbs2-0144" title="Kim H-B, Myung S-K, Lee Y-J, Park B-J. Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials. Journal of Human Nutrition and Dietetics2018;31(2):168-77.">Kim 2018</a>; <a href="./references#CD011564-bbs2-0121" title="HaririM , ZohdiS . Effect of vitamin D on non-alcoholic fatty liver disease: a systematic review of randomized controlled clinical trials. International Journal of Preventive Medicine2019;10(1):14.">Hariri 2019</a>; <a href="./references#CD011564-bbs2-0133" title="Hu Y-C, Wang W-W, Jiang W-Y, Li C-Q, Guo J-C, Xun Y-H. Low vitamin D levels are associated with high viral loads in patients with chronic hepatitis B: a systematic review and meta-analysis. BMC Gastroenterology2019;19(1):84.">Hu 2019</a>; <a href="./references#CD011564-bbs2-0168" title="Mansour-GhanaeiF , PourmasoumiM , HadiA , Ramezani-JolfaieN , JoukarF . The efficacy of vitamin D supplementation against nonalcoholic fatty liver disease: a meta-analysis. Journal of Dietary Supplements2019;17(4):467-85.">Mansour‐Ghanaei 2019</a>; <a href="./references#CD011564-bbs2-0192" title="SharifiN , AmaniR . Vitamin D supplementation and non-alcoholic fatty liver disease: a critical and systematic review of clinical trials. Critical Reviews in Food Science and Nutrition2019;59(4):693-703.">Sharifi 2019</a>). Results of our previous systematic reviews indicate that vitamin D<sub>3</sub> supplementation may potentially prolong life span in adults from the general population (<a href="./references#CD011564-bbs2-0063" title="BjelakovicG , GluudLL , NikolovaD , WhitfieldK , WetterslevJ , SimonettiRG , et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD007470. [DOI: 10.1002/14651858.CD007470.pub3]">Bjelakovic 2014a</a>), but this observation has been effectively contradicted by recent large randomised clinical trials (<a href="./references#CD011564-bbs2-0190" title="ScraggR , StewartAW , WaayerD , LawesCMM , ToopL , SluyterJ , et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study: a randomized clinical trial. JAMA Cardiology2017;2(6):608-16.">Scragg 2017</a>; <a href="./references#CD011564-bbs2-0167" title="MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. New England Journal of Medicine2019;380(1):33-44.">Manson 2019</a>), and vitamin D does not seem to have an effect on cancer occurrence and cardiovascular diseases (<a href="./references#CD011564-bbs2-0064" title="BjelakovicG , GluudLL , NikolovaD , WhitfieldK , KrsticG , WetterslevJ , et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD007469. [DOI: 10.1002/14651858.CD007469.pub2]">Bjelakovic 2014b</a>; <a href="./references#CD011564-bbs2-0191" title="ScraggR , KhawKT , ToopL , SluyterJ , LawesCMM , WaayerD , et al. Monthly high-dose vitamin D supplementation and cancer risk: a post hoc analysis of the Vitamin D Assessment randomized clinical trial. JAMA Oncology2018;4(11):e182178.">Scragg 2018</a>; <a href="./references#CD011564-bbs2-0167" title="MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. New England Journal of Medicine2019;380(1):33-44.">Manson 2019</a>; <a href="./references#CD011564-bbs2-0060" title="Bischoff-FerrariHA , VellasB , RizzoliR , KressigRW , Da SilvaJAP , BlauthM , et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA2020;324(18):1855-68.">Bischoff‐Ferrari 2020</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011564-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011564-sec-0014"></div> <p>To assess the beneficial and harmful effects of vitamin D supplementation in adults with chronic liver diseases. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011564-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011564-sec-0015"></div> <section id="CD011564-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011564-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised clinical trials, irrespective of blinding, publication status, or language.</p> </section> <section id="CD011564-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults (aged 18 years or over) diagnosed with a chronic liver disease (alcoholic, non‐alcoholic fatty liver disease, post‐hepatitis B and C, cholestatic, inherited, and autoimmune diseases). </p> </section> <section id="CD011564-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD011564-sec-0020"> <h5 class="title">Experimental</h5> <p>Vitamin D at any dose and for any duration, administered as monotherapy or in combination with calcium. The route of administration could be enteral (orally) or parenteral. Vitamin D could be administered as supplemental vitamin D (vitamin D<sub>3</sub> (cholecalciferol) or vitamin D<sub>2</sub> (ergocalciferol)) or as an active form of vitamin D (1α‐hydroxyvitamin D (alfacalcidol), 25‐hydroxyvitamin D (calcidiol), or 1,25‐dihydroxyvitamin D (calcitriol)). </p> </section> <section id="CD011564-sec-0021"> <h5 class="title">Control</h5> <p>Placebo (identical in appearance and smell) or no intervention.</p> <p>Concomitant interventions were allowed if used equally in all intervention groups.</p> </section> </section> <section id="CD011564-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD011564-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011564-list-0001"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Liver‐related mortality.</p> </li> <li> <p>Serious adverse events. Depending on the availability of data, we attempted to classify adverse events as serious or non‐serious. Serious adverse events were defined as any outward medical occurrence that was life‐threatening; resulted in death, or persistent or significant disability; or any medical event that may have jeopardised the person; or required intervention to prevent it (<a href="./references#CD011564-bbs2-0134" title="International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR &amp; ICH Guidelines. Vol. 1. Philadelphia: Barnett International/PAREXEL, 1997.">ICH‐GCP 1997</a>). We considered all other adverse events as non‐serious (see <a href="#CD011564-sec-0024">Secondary outcomes</a> below). </p> </li> </ul> </p> </section> <section id="CD011564-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011564-list-0002"> <li> <p>Liver‐related morbidity (gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, ascites, liver cancer). </p> </li> <li> <p>Health‐related quality of life (any valid continuous outcome scale used by the trialists).</p> </li> <li> <p>Non‐serious adverse events.</p> </li> <li> <p>Failure of virological response at week four (without rapid virological response), at week 12 (without early virological response), and at six months after treatment (sustained virological response) (e.g. without clearance of hepatitis B virus DNA (HBV‐DNA) or hepatitis C virus ribonucleic acid (HCV‐RNA) from serum). </p> </li> <li> <p>Acute cellular rejection in liver transplant recipients.</p> </li> <li> <p>Vitamin D status.</p> </li> <li> <p>Bone mineral density.</p> </li> <li> <p>Biochemical indices (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatases, gamma‐glutamyl transpeptidase, albumin, bilirubin, triglyceride, cholesterol, calcium, glucose, phosphorus, adiponectin, insulin, parathyroid hormone, C‐reactive protein). </p> </li> </ul> </p> <section id="CD011564-sec-0025"> <h6 class="title">Covariates, effect modifiers, and confounders</h6> <p>We recorded any possible covariates, effect modifiers, and confounders such as dosage and form of vitamin D, dosing schedule, duration of supplementation, duration of follow‐up, mean age, risk of bias, calcium co‐administration, other medications, compliance, and attrition. </p> </section> <section id="CD011564-sec-0026"> <h6 class="title">Timing of outcome measurement</h6> <p>We applied no restrictions regarding duration of the intervention or length of follow‐up. We assessed outcome data at the end of the trial follow‐up period. </p> </section> </section> </section> </section> <section id="CD011564-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011564-sec-0028"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register (maintained and searched internally by the Cochrane Hepato‐Biliary Group Information Specialist via the Cochrane Register of Studies Web; 24 November 2020), the Cochrane Central Register of Controlled Trials (CENTRAL; 24 November 2020) in the Cochrane Library, MEDLINE Ovid (1946 to 24 November 2020), Embase Ovid (1974 to 24 November 2020), LILACS (Latin American and Caribbean Health Science Information database) (BIREME; 1982 to 24 November 2020), Science Citation Index Expanded (Web of Science, 1900 to 24 November 2020), and Conference Proceedings Citation Index‐Science (Web of Science; 1990 to 24 November 2020). The search strategies with the time spans of the searches are provided in <a href="./appendices#CD011564-sec-0123">Appendix 1</a>. </p> <p>We also searched ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>) and the World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>). There were no language limitations. </p> </section> <section id="CD011564-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We contacted experts and the main manufacturers of vitamin D to enquire as to unpublished randomised trials. We identified additional trials by searching the reference lists of the included trials and systematic reviews, meta‐analyses, and health technology assessment reports. </p> </section> </section> <section id="CD011564-sec-0030"> <h3 class="title" id="CD011564-sec-0030">Data collection and analysis</h3> <p>One review author (MB) performed the electronic searches. Two review authors (GB and DN) independently participated in the manual searches and identified trials eligible for inclusion from the search results. </p> <section id="CD011564-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MB and GB) independently scanned the abstract, title, or both of every record retrieved to identify studies for further assessment. We investigated all potentially relevant articles as full text. One review author (GB) listed the excluded studies along with the reasons for their exclusion. When a discrepancy occurred in the trial selection, we consulted one review author (CG) to reach consensus. If resolving disagreement was not possible, we added the article to those 'awaiting assessment', and contacted the trial authors for clarification. We also contacted trial authors when information required to make an assessment was not found in the published trial reports. Inter‐rater agreement for trial selection was measured using the Kappa statistic (<a href="./references#CD011564-bbs2-0078" title="CohenJ . A coefficient of agreement for nominal scales. Educational and Psychological Measurement1960;20:37-46.">Cohen 1960</a>). Agreement between the review authors was very good (Kappa = 0.85). We included an adapted PRISMA flow diagram of study selection (<a href="./references#CD011564-bbs2-0170" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLOS Medicine2009;6(7):e1000097.">Moher 2009</a>). </p> </section> <section id="CD011564-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>For studies that fulfilled the inclusion criteria, three review authors (GB, DN, and MB) independently extracted the relevant population, intervention characteristics, and risk of bias components using standard data extraction templates. We identified any duplicate publications. Disagreements were resolved by discussion or by consultation with another review author (CG) when required. </p> <section id="CD011564-sec-0033"> <h5 class="title">Dealing with duplicate publications and companion papers</h5> <p>In the case of duplicate publications and companion papers of a primary study, we maximised our yield of information by simultaneous evaluation of all available data. </p> </section> </section> <section id="CD011564-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (GB and DN) independently assessed the risk of bias of each included trial according to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011564-bbs2-0126" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>), and methodological studies (<a href="https://archie.cochrane.org/sections/documents/view?version=z1503052256274343291629893139318&amp;format=REVMAN#REF-Schulz-1995" target="_blank">Schulz 1995</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1503052256274343291629893139318&amp;format=REVMAN#REF-Moher-1998" target="_blank">Moher 1998</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1503052256274343291629893139318&amp;format=REVMAN#REF-Kjaergard-2001" target="_blank">Kjaergard 2001</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1503052256274343291629893139318&amp;format=REVMAN#REF-Wood-2008" target="_blank">Wood 2008</a>; <a href="./references#CD011564-bbs2-0182" title="SavovićJ , JonesH , AltmanD , HarrisR , JűniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment2012;16(35):1-82.">Savović 2012a</a>; <a href="./references#CD011564-bbs2-0183" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savović 2012b</a>; <a href="./references#CD011564-bbs2-0185" title="SavovićJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJPT , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology2018;187(5):1113–22.">Savović 2018b</a>). We used the following definitions in our risk of bias assessment. </p> <section id="CD011564-sec-0035"> <h5 class="title">Allocation sequence generation</h5> <p> <ul id="CD011564-list-0003"> <li> <p>Low risk of bias: study authors performed sequence generation using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the study. </p> </li> <li> <p>Unclear risk of bias: method of sequence generation not mentioned.</p> </li> <li> <p>High risk of bias: sequence generation method was not random.</p> </li> </ul> </p> </section> <section id="CD011564-sec-0036"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD011564-list-0004"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. A central and independent randomisation unit controlled allocation. Investigators were unaware of allocation sequence (e.g. if allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Unclear risk of bias: the method used to conceal allocation is not mentioned so that intervention allocations may have been foreseen before, or during, enrolment. </p> </li> <li> <p>High risk of bias: it is likely that the investigators who assigned the participants knew the allocation sequence. </p> </li> </ul> </p> </section> <section id="CD011564-sec-0037"> <h5 class="title">Blinding of participants and personnel</h5> <p> <ul id="CD011564-list-0005"> <li> <p>Low risk of bias: any of the following: no blinding or incomplete blinding, but we judged that the outcome was not likely to be influenced by lack of blinding; or blinding of participants and key study personnel ensured, and it was unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information to permit judgement of 'low risk' or 'high risk'; or the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: any of the following: no blinding or incomplete blinding, and the outcome was likely to be influenced by lack of blinding; or blinding of key study participants and personnel attempted, but it was likely that the blinding could have been broken, and the outcome was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD011564-sec-0038"> <h5 class="title">Blinded outcome assessment</h5> <p> <ul id="CD011564-list-0006"> <li> <p>Low risk of bias: any of the following: no blinding of outcome assessment, but we judged that the outcome measurement was not likely to be influenced by lack of blinding; or blinding of outcome assessment ensured, and it was unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information to permit judgement of 'low risk' or 'high risk'; or the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: any of the following: no blinding of outcome assessment, and the outcome measurement was likely to be influenced by lack of blinding; or blinding of outcome assessment, but it was likely that the blinding could have been broken, and the outcome measurement was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD011564-sec-0039"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD011564-list-0007"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The study used sufficient methods, such as multiple imputation, to handle missing data. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD011564-sec-0040"> <h5 class="title">Selective outcome reporting</h5> <p> <ul id="CD011564-list-0008"> <li> <p>Low risk of bias: the trial reported all predefined outcomes. If the original trial protocol was available, the outcomes should have been those called for in that protocol. If the trial protocol was obtained from a trial registry (e.g. <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>), the outcomes sought should have been those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. If the trial protocol was registered after the trial had begun, we did not consider those outcomes to be reliable. </p> </li> <li> <p>Unclear risk of bias: the study authors did not report all predefined outcomes fully, or it was unclear whether the study authors recorded data on these outcomes. </p> </li> <li> <p>High risk of bias: the study authors did not report one or more of the predefined outcomes. </p> </li> </ul> </p> </section> <section id="CD011564-sec-0041"> <h5 class="title">Other bias</h5> <p> <ul id="CD011564-list-0009"> <li> <p>Low risk of bias: the trial appeared to be free of other components (e.g. academic bias) that could put it at risk of bias. </p> </li> <li> <p>Unclear risk of bias: the trial may or may not have been free of other components that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: there were other factors in the trial that could put it at risk of bias (e.g. authors had conducted trials on the same topic). </p> </li> </ul> </p> </section> <section id="CD011564-sec-0042"> <h5 class="title">Overall risk of bias</h5> <p>We judged a trial to be at overall low risk of bias if we assessed the trial at low risk of bias for all of the above domains. We judged a trial to be at high risk of bias if we assessed the trial as having an unclear risk of bias or a high risk of bias in one or more of the risk of bias domains. </p> </section> </section> <section id="CD011564-sec-0043"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011564-sec-0044"> <h5 class="title">Dichotomous outcomes</h5> <p>For dichotomous outcomes, we calculated and presented risk ratios (RR) with 95% confidence intervals (CI). We planned to calculate and present Peto's odds ratio for rare events such as all‐cause mortality and liver‐related mortality. As there were no differences between the results with Peto's odds ratio and the RR for these two outcomes, we presented the results with RR (<a href="./references#CD011564-bbs2-0083" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). </p> </section> <section id="CD011564-sec-0045"> <h5 class="title">Continuous outcomes</h5> <p>For continuous outcomes, we calculated and presented mean differences (MD) with 95% CI. </p> <p>In the case of time‐to‐event data, we planned to plot and meta‐analyse estimates of hazard ratios (HR) and 95% CIs as presented in the study reports using the generic inverse‐variance method in Review Manager 5 (<a href="./references#CD011564-bbs2-0180" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> </section> <section id="CD011564-sec-0046"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant as randomised to the intervention group of a clinical trial. In trials with one experimental and one control parallel‐group design, we compared the experimental intervention group versus the control group. In trials with parallel‐group design with more than two intervention groups, we compared the combined vitamin D groups versus the placebo or no intervention group. </p> <p>For cross‐over trials, we planned to include the relevant data from the first trial period to avoid residual effects from the treatment (<a href="./references#CD011564-bbs2-0125" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>; <a href="./references#CD011564-bbs2-0126" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). In order to avoid repeated observations on trial participants, we recorded all time points for these observations, but we used the trial data at the longest follow‐up for analysis (<a href="./references#CD011564-bbs2-0125" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>; <a href="./references#CD011564-bbs2-0126" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> <p>We planned to include cluster‐randomised trials and assess risk of bias as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011564-bbs2-0125" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>; <a href="./references#CD011564-bbs2-0126" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD011564-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to obtain relevant missing data from study authors whenever we lacked important numerical data, such as number of screened or randomised participants, or if there was a lack of data regarding the performance of intention‐to‐treat (ITT) analyses, or data on as‐treated or per‐protocol participant analyses, which prevented us from performing our analyses appropriately. We investigated attrition rates (e.g. dropouts, losses to follow‐up, and withdrawals) and critically appraised issues of missing data (e.g. last‐observation‐carried‐forward and imputation methods). </p> <p>Regarding the primary outcomes, we included trial participants with incomplete or missing data in sensitivity analyses by imputing them according to the following scenarios (<a href="./references#CD011564-bbs2-0131" title="HollisS , CampbellF . What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Ed.)1999;319(7211):670-4.">Hollis 1999</a>). </p> <p> <ul id="CD011564-list-0010"> <li> <p>Extreme‐case analysis favouring the experimental intervention (best‐worse‐case scenario): none of the dropouts/participants lost from the experimental arm, but all the dropouts/participants lost from the control arm experienced the outcome, including all randomised participants in the denominator. </p> </li> <li> <p>Extreme‐case analysis favouring the control intervention (worst‐best‐case scenario): all dropouts/participants lost from the experimental arm, but none from the control arm experienced the outcome, including all randomised participants in the denominator. </p> </li> </ul> </p> </section> <section id="CD011564-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We identified heterogeneity by visual inspection of the forest plots, and by using a standard Chi<sup>2</sup> test and a significance level of α = 0.1 (<a href="./references#CD011564-bbs2-0123" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>; <a href="./references#CD011564-bbs2-0124" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ (Clinical Research Ed.)2003;327:557-60.">Higgins 2003</a>). </p> <p>We interpreted the I<sup>2</sup> statistic as follows (<a href="./references#CD011564-bbs2-0126" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>): </p> <p> <ul id="CD011564-list-0011"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>For heterogeneity adjustment of the required information size in the Trials Sequential Analysis, we used diversity (D<sub> 2</sub> ), as the I<sup>2</sup> statistic used for this purpose consistently underestimates the required information size (<a href="./references#CD011564-bbs2-0216" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>). </p> <p>When we found considerable heterogeneity, we attempted to determine the potential reasons for it by examining the individual trial and subgroup characteristics. </p> </section> <section id="CD011564-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>To assess the potential existence of publication bias, we planned to use a funnel plot in an exploratory data analysis of the outcome all‐cause mortality, if 10 or more trials were included (<a href="./references#CD011564-bbs2-0126" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). There are several explanations for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design of small trials, and publication bias. </p> <p>We performed adjusted rank correlation, <a href="./references#CD011564-bbs2-0058" title="BeggCB , MazumdarM . Operating characteristics of a rank correlation test for publication bias. Biometrics1994;50(4):1088-101.">Begg 1994</a>, and a regression asymmetry test, <a href="./references#CD011564-bbs2-0086" title="EggerM , DaveySG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315(7109):629-34.">Egger 1997</a>, for detection of bias. We considered a P value of less than 0.10 as significant in these analyses. </p> </section> <section id="CD011564-sec-0050"> <h4 class="title">Data synthesis</h4> <section id="CD011564-sec-0051"> <h5 class="title">Meta‐analysis</h5> <p>We performed statistical analyses according to the guidelines described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011564-bbs2-0126" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> <p>For the statistical analyses, we used Review Manager 5 (<a href="./references#CD011564-bbs2-0180" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>), Trial Sequential Analysis version 0.9.5.10 beta (<a href="./references#CD011564-bbs2-0207" title="Copenhagen Trial UnitTrial Sequential Analysis. Copenhagen Trial Unit, Version 0.9.5.10 Beta. Copenhagen: Copenhagen Trial Unit, 2017. ctu.dk/tsa/downloads/.">TSA 2017</a>), Stata 8.2 (<a href="./references#CD011564-bbs2-0197" title="College Station, TX: StataCorp LPIntercooled Stata 8.2 for Windows. College Station, TX: StataCorp LP, 2005.">StataCorp 2005</a>), and SigmaStat 3.0 (<a href="./references#CD011564-bbs2-0194" title="Systat Software Inc.Sigma Stat 3.0. Systat Software Inc., 2003.">Sigma Stat 2003</a>). We analysed the data using both fixed‐effect (<a href="./references#CD011564-bbs2-0084" title="DeMetsDL . Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341-50.">DeMets 1987</a>), and random‐effects (<a href="./references#CD011564-bbs2-0085" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>), models for meta‐analyses. We presented the results of the random‐effects model analyses. If there were statistically significant discrepancies in the results (e.g. one model giving a significant intervention effect, and the other model giving no significant intervention effect), we presented both models, but considered the more conservative point estimate of the two as the most informative (<a href="./references#CD011564-bbs2-0138" title="JakobsenJC , GluudC , WinkelP , LangeT , WetterslevJ . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120.">Jakobsen 2014a</a>). The more conservative point estimate is the estimate closest to one (for dichotomous outcomes) or zero effect (for continuous outcomes). If the two‐point estimates were equal, we used the estimate with the widest CI as our main result of the two analyses (<a href="./references#CD011564-bbs2-0138" title="JakobsenJC , GluudC , WinkelP , LangeT , WetterslevJ . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120.">Jakobsen 2014a</a>). For dichotomous outcomes, we calculated RR, and for continuous outcomes we calculated MD or standardised mean difference (SMD) for health‐related quality of life. For all association measures, we used 95% CIs. We performed the analyses using the ITT principle, that is including all randomised participants irrespective of completeness of data. Participants with missing data were included in the analyses using a carry forward of the last observed response. Accordingly, participants who had been lost to follow‐up were counted as being alive. </p> <p>We compared the intervention effects in subgroups of trials using the method described by Borenstein and colleagues (<a href="./references#CD011564-bbs2-0069" title="BorensteinM , HedgesLV , HigginsT , RothsteinHR . Introduction to Meta-Analysis. Chichester (UK): John Wiley &amp; Sons, 2009.">Borenstein 2009</a>), and implemented it in Review Manager 5 analyses. </p> </section> </section> <section id="CD011564-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct a subgroup analysis comparing trials at low risk of bias to trials at unclear or high risk of bias in order to assess the risk of bias to intervention effects (<a href="./references#CD011564-bbs2-0188" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD011564-bbs2-0169" title="MoherD , PhamB , JonesA , CookDJ , JadadA , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD011564-bbs2-0147" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>; <a href="./references#CD011564-bbs2-0219" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601-5.">Wood 2008</a>; <a href="./references#CD011564-bbs2-0182" title="SavovićJ , JonesH , AltmanD , HarrisR , JűniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment2012;16(35):1-82.">Savović 2012a</a>; <a href="./references#CD011564-bbs2-0183" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savović 2012b</a>; <a href="./references#CD011564-bbs2-0185" title="SavovićJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJPT , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology2018;187(5):1113–22.">Savović 2018b</a>). Given that all trials were at high risk of bias, we were not able to conduct this subgroup analysis. </p> <p>We conducted the following subgroup analyses.</p> <p> <ul id="CD011564-list-0012"> <li> <p>According to the aetiology of the chronic liver disease, as vitamin D may have a different effect on the outcome all‐cause mortality in people with chronic liver disease of different aetiology (e.g. non‐alcoholic fatty liver disease, chronic hepatitis C, liver cirrhosis, liver transplant recipients): </p> <ul id="CD011564-list-0013"> <li> <p>people with non‐alcoholic fatty liver disease compared to people with chronic hepatitis C; </p> </li> <li> <p>people with non‐alcoholic fatty liver disease compared to people with liver cirrhosis;</p> </li> <li> <p>people with non‐alcoholic fatty liver disease compared to liver transplant recipients.</p> </li> </ul> </li> <li> <p>According to vested interests. Trials at low risk of vested interests compared to trials at unclear or high risk of vested interests (<a href="./references#CD011564-bbs2-0160" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3]">Lundh 2017</a>). </p> </li> <li> <p>According to vitamin D status at entry (vitamin D sufficient compared to vitamin D insufficient participants). As some participants in some trials had baseline 25‐hydroxyvitamin D levels at or above vitamin D adequacy (20 ng/mL serum), whilst some participants in other trials were vitamin D insufficient (less than 20 ng/mL serum), we conducted this post hoc subgroup analysis. </p> </li> <li> <p>According to the different forms of vitamin D used for supplementation, as vitamin D form may have a different effect on the outcome all‐cause mortality: </p> <ul id="CD011564-list-0014"> <li> <p>vitamin D<sub>3</sub> compared with placebo or no intervention; </p> </li> <li> <p>vitamin D<sub>2</sub> compared with placebo or no intervention; </p> </li> <li> <p>25‐dihydroxyvitamin D compared with placebo or no intervention;</p> </li> <li> <p>1,25‐dihydroxyvitamin D compared with placebo or no intervention.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD011564-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>In addition to the sensitivity analyses described in Dealing with missing data, we used Trial Sequential Analysis as a sensitivity analysis to assess imprecision. </p> <section id="CD011564-sec-0054"> <h5 class="title">Trial Sequential Analysis</h5> <p>We controlled apparently significant beneficial and harmful intervention effects (potential type I errors) and neutral intervention effects (potential type II errors) with Trial Sequential Analysis to evaluate if these effects could be caused by random errors (<a href="./references#CD011564-bbs2-0070" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology2008;61(8):763-9.">Brok 2008</a>; <a href="./references#CD011564-bbs2-0215" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>; <a href="./references#CD011564-bbs2-0071" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology2009;38(1):287-98.">Brok 2009</a>; <a href="./references#CD011564-bbs2-0203" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology2009;38(1):276-86.">Thorlund 2009</a>; <a href="./references#CD011564-bbs2-0216" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>; <a href="./references#CD011564-bbs2-0204" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PLOS ONE2011;6(10):e25491.">Thorlund 2011</a>; <a href="./references#CD011564-bbs2-0205" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/wp-content/uploads/2020/12/tsa_manual_ENG.pdf 2017 (accessed 2 September 2020).">Thorlund 2017</a>; <a href="./references#CD011564-bbs2-0207" title="Copenhagen Trial UnitTrial Sequential Analysis. Copenhagen Trial Unit, Version 0.9.5.10 Beta. Copenhagen: Copenhagen Trial Unit, 2017. ctu.dk/tsa/downloads/.">TSA 2017</a>; <a href="./references#CD011564-bbs2-0217" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>). The underlying assumption of Trial Sequential Analysis is that testing for significance may be performed each time a new trial is added to the meta‐analysis. We added the trials according to the year of publication, and if more than one trial was published in a year, we added trials alphabetically according to the last name of the first author. </p> <p>We used Trial Sequential Analysis because cumulative meta‐analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<a href="./references#CD011564-bbs2-0215" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>). To control for random errors, we calculated the required information size (i.e. the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect) (<a href="./references#CD011564-bbs2-0215" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>). The required information size calculation should account for the diversity, present in the meta‐analysis (<a href="./references#CD011564-bbs2-0215" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>; <a href="./references#CD011564-bbs2-0216" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>). We assessed the diversity‐adjusted required information size (DARIS) for the three primary and the first four secondary outcomes presented in the <a href="./full#CD011564-tbl-0001">summary of findings Table 1</a>, by adjusting for multiplicity, using a P value of 0.125, a risk of type II error of 10%, and the observed diversity of the included trials in the random‐effects model meta‐analysis (<a href="./references#CD011564-bbs2-0138" title="JakobsenJC , GluudC , WinkelP , LangeT , WetterslevJ . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120.">Jakobsen 2014a</a>). For dichotomous outcomes, we used the proportion in the control group in the meta‐analysis and a relative risk reduction of 20%. For the continuous outcome health‐related quality of life, we would have used the standard deviation (SD) divided by 2 as the minimal relevant difference plus the SD of the difference for calculating the DARIS. </p> <p>We constructed trial sequential monitoring boundaries for benefit, harm, or futility, based on the DARIS (<a href="./references#CD011564-bbs2-0205" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/wp-content/uploads/2020/12/tsa_manual_ENG.pdf 2017 (accessed 2 September 2020).">Thorlund 2017</a>). These boundaries determined the statistical inference one may draw regarding the cumulative meta‐analysis that has not reached the required information size. If the cumulative Z‐curve crosses the trial sequential monitoring boundary for benefit or harm before the diversity‐adjusted required information size is reached, firm evidence may be established, and further trials may be superfluous. In contrast, if the boundary is not surpassed, it is most likely necessary to continue doing trials to detect or reject a certain intervention effect. This can be determined by assessing if the cumulative Z‐curve crosses the trial sequential monitoring boundaries for futility. A more detailed description of Trial Sequential Analysis can be found at <a href="http://www.ctu.dk/tsa/" target="_blank">www.ctu.dk/tsa/</a> (<a href="./references#CD011564-bbs2-0205" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/wp-content/uploads/2020/12/tsa_manual_ENG.pdf 2017 (accessed 2 September 2020).">Thorlund 2017</a>), and in <a href="./references#CD011564-bbs2-0217" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>. </p> <p>In Trial Sequential Analysis, imprecision is downgraded two levels if the accrued number of participants is below 50% of the DARIS, and one level if it is between 50% and 100% of DARIS. We did not downgrade if the cumulative Z‐curve crossed the monitoring boundaries for benefit, harm, or futility, or if DARIS was reached. </p> <p>See also <a href="#CD011564-sec-0047">Dealing with missing data</a>. </p> </section> </section> <section id="CD011564-sec-0055"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created summary of findings tables using <a href="./references#CD011564-bbs2-0101" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 4 November 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a> (<a href="./references#CD011564-bbs2-0101" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 4 November 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). We used the GRADE approach to assess the quality of a body of evidence, that is the extent of certainty on which one can be confident that an estimate of effect or association reflects the item being assessed. The certainty of a body of evidence considers within‐study risk of bias, directness of the evidence (population, intervention, control, outcomes), unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses), imprecision of results (wide CIs, optimal information size criterion), and risk of publication bias (<a href="./references#CD011564-bbs2-0056" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6. [PMID: 21208779]">Balshem 2011</a>; <a href="./references#CD011564-bbs2-0107" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [PMID: 21195583]">Guyatt 2011a</a>; <a href="./references#CD011564-bbs2-0108" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395-400. [PMID: 21194891]">Guyatt 2011b</a>; <a href="./references#CD011564-bbs2-0109" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso-CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407-15. [PMID: 21247734]">Guyatt 2011c</a>; <a href="./references#CD011564-bbs2-0110" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology2011;64(12):1277-82. [PMID: 21802904]">Guyatt 2011d</a>; <a href="./references#CD011564-bbs2-0111" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines: 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [PMID: 21839614]">Guyatt 2011e</a>; <a href="./references#CD011564-bbs2-0112" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology2011;64(12):1294-302. [PMID: 21803546]">Guyatt 2011f</a>; <a href="./references#CD011564-bbs2-0113" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology2011;64(12):1303-10. [PMID: 21802903]">Guyatt 2011g</a>; <a href="./references#CD011564-bbs2-0114" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso-CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311-6. [PMID: 21802902]">Guyatt 2011h</a>; <a href="./references#CD011564-bbs2-0115" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso-CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151-7.">Guyatt 2013a</a>; <a href="./references#CD011564-bbs2-0116" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes. Journal of Clinical Epidemiology2013;66(2):158-72.">Guyatt 2013b</a>; <a href="./references#CD011564-bbs2-0117" title="GuyattGH , ThorlundK , OxmanAD , WalterSD , PatrickD , FurukawaTA , et al. GRADE guidelines: 13. Preparing summary of findings tables - continuous outcomes. Journal of Clinical Epidemiology2013;66(2):173-83.">Guyatt 2013c</a>; <a href="./references#CD011564-bbs2-0118" title="GuyattG , AndrewsJ , OxmanAD , AldersonP , DahmP , Falck-YtterY , et al. GRADE guidelines: 15. Going from evidence to recommendations: the significance and presentation of recommendations. Journal of Clinical Epidemiology2013;66(7):719-25.">Guyatt 2013d</a>; <a href="./references#CD011564-bbs2-0172" title="MustafaRA , SantessoN , BrozekJ , AklEA , WalterSD , NormanG , et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology2013;66(7):736-42. [PMID: 23623694]">Mustafa 2013</a>; <a href="./references#CD011564-bbs2-0189" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>; <a href="./references#CD011564-bbs2-0119" title="GuyattGH , EbrahimS , Alonso-CoelloP , JohnstonBC , MathioudakisAG , BrielM , et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology2017;87:14-22. [PMID: 28529188]">Guyatt 2017</a>). We presented the following outcomes: all‐cause mortality, liver‐related mortality, serious adverse events, liver‐related morbidity, health‐related quality of life, non‐serious adverse events, and failure of sustained virological response. After each outcome, we provided the mean and range of follow‐up, or end of follow‐up when there was only one trial that provided data. </p> <p>These grades of certainty are defined as follows.</p> <p> <ul id="CD011564-list-0015"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011564-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011564-sec-0056"></div> <section id="CD011564-sec-0057"> <h3 class="title">Description of studies</h3> <p>In the previous version of this review, we included 15 randomised trials (described in 19 references) with 1034 participants providing data for analyses (<a href="./references#CD011564-bbs2-0224" title="BjelakovicG , NikolovaD , BjelakovicM , GluudC . Vitamin D supplementation for chronic liver diseases in adults. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD011564. [DOI: 10.1002/14651858.CD011564.pub2]">Bjelakovic 2017</a>). As described below, our updated searches resulted in the inclusion of an additional 12 randomised trials. </p> <section id="CD011564-sec-0058"> <h4 class="title">Results of the search</h4> <p>We identified 4672 references of possible interest through the updated electronic searches of the Cochrane Hepato‐Biliary Group Controlled Trials Register (134 records); the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (1192 records); MEDLINE Ovid (468 records); Embase Ovid (1900 records); LILACS (28 records); and Science Citation Index Expanded and Conference Proceedings Citation Index‐Science (950 records). We identified an additional two ongoing trials through searching databases of ongoing trials, and four records from reference lists. We excluded 961 duplicates and 3683 clearly irrelevant references through reading of abstracts. Accordingly, we retrieved 34 references for further assessment. Of these, we excluded 19 references because they were not randomised trials, and three references because they did not fulfil our inclusion criteria. </p> <p>Consequently, we included 12 new randomised trials (described in 12 references) in this updated review version; a total of 27 trials (31 references) with 1979 participants provided data for our analyses (<a href="#CD011564-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011564-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011564-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011564-sec-0059"> <h4 class="title">Included studies</h4> <p>For details of the included studies, see <a href="./references#CD011564-sec-0134" title="">Characteristics of included studies</a>; <a href="#CD011564-tbl-0002">Table 1</a>; <a href="#CD011564-tbl-0003">Table 2</a>; <a href="#CD011564-tbl-0004">Table 3</a>. </p> <div class="table" id="CD011564-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included trials (I)</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Protocol</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Groups</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias<br/>risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Blinding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants<br/>(n)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Women<br/>(%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean<br/>age (years)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n: number of participants<br/>NI: no intervention<br/>PL: placebo </p> </div> </div> <div class="table" id="CD011564-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included trials (II)</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome measures</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sponsor</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Country</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Israel</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver steatosis, liver function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1, 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical indices, HOMA, FibroScan measurement</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical indices</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver steatosis, liver function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD (NASH)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver steatosis, liver function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum 25‐hydroxyvitamin D, adiponectin, HOMA‐IR, liver enzymes, and change in grade of NAFLD </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body weight, BMI, insulin resistance, dyslipidaemia, hepatic enzymes, CRP, and adiponectin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pakistan</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1, 2, 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Republic of Korea</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver cirrhosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum levels of T‐helper cells associated cytokines</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum fibrotic markers</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver function, body fat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver cirrhosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 2 or 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Israel</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver cirrhosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D status, liver function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insulin resistance and serum ALT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver function, insulin resistance index</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver cirrhosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary biliary cirrhosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical indices, liver steatosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1, 2, 3, 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver transplant recipients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute cellular rejection rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ALT: alanine aminotransferase<br/>BMI: body mass index<br/>CRP: C‐reactive protein<br/>HOMA‐IR: homeostatic model assessment for insulin resistance<br/>NAFLD: non‐alcoholic fatty liver disease<br/>NASH: non‐alcoholic steatohepatitis </p> </div> </div> <div class="table" id="CD011564-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included studies (III)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Vitamin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Calcium</b> <br/>(<b>mg)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Treatment<br/>(weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Follow‐up<br/>(weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Co‐intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>D<sub>3</sub> </b> <br/>(<b>IU)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>D<sub>2</sub> </b> <br/>(<b>IU)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>25(OH)D</b> <br/>(IU<b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1,25(OH)<sub>2</sub>D</b> <br/>(<b>µg)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV, SP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly and daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intramuscularly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E 400 IU/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24, 48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48, 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300,000; 800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intramuscularly and orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose; daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60,000; 80,000; 100,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60,000; 80,000; 100,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intramuscularly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice a week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lifestyle modification</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>1,25(OH)<sub>2</sub>D: calcitriol<br/>25(OH)D: calcidiol<br/>IU: international unit<br/>PEG‐IFN: pegylated‐interferon<br/>RBV: ribavirin<br/>SP: simeprevir </p> </div> </div> <p>All 27 included trials used a parallel‐group design, with two (<a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>: <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>: <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>) or three intervention groups (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>; <a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>). The trials were published from 1984 to 2019 (<a href="#CD011564-tbl-0002">Table 1</a>). </p> <p>The trials were conducted in Africa (<a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>), Asia (<a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>, <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>); Europe (<a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>), and North America (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>). Eleven trials were conducted in high‐income countries (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>; <a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>), and 16 trials were conducted in middle‐income countries (<a href="#CD011564-tbl-0003">Table 2</a>) (<a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>). </p> <section id="CD011564-sec-0060"> <h5 class="title">Participants</h5> <p>A total of 1979 participants were randomly assigned in the 27 trials. The number of participants in each trial ranged from 18 to 148 (median 84). The mean age of participants was 48 years (range 28 years to 61 years). The mean proportion of women was 44% (<a href="#CD011564-tbl-0002">Table 1</a>). </p> <p>Ten trials included participants with chronic hepatitis C (<a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>); five trials participants with liver cirrhosis (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>; <a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>); 11 trials participants with non‐alcoholic fatty liver disease (<a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>); and one trial liver transplant recipients (<a href="#CD011564-tbl-0003">Table 2</a>) (<a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>). </p> <p>All of the included trials reported the baseline vitamin D status of participants based on serum 25‐hydroxyvitamin D levels. Participants in nine trials had baseline 25‐hydroxyvitamin D levels at or above vitamin D adequacy (20 ng/mL) (<a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>). Participants in the remaining 18 trials had baseline 25‐hydroxyvitamin D levels considered to be vitamin D insufficient (less than 20 ng/mL) (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>; <a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>). </p> </section> <section id="CD011564-sec-0061"> <h5 class="title">Experimental interventions</h5> <p>One trial did not report form and dose of vitamin D (<a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>). One trial with three intervention groups administered 1,25‐dihydroxyvitamin D combined with calcium gluconate in one intervention group, calcium gluconate alone in another intervention group, and placebo in a third group (<a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>). We thus compared the 1,25‐dihydroxyvitamin D plus calcium gluconate group versus the calcium gluconate group and placebo group combined. Another trial with three intervention groups used vitamin D<sub>3</sub> singly in one intervention group, vitamin D<sub>3</sub> combined with calcium carbonate in another intervention group, and placebo in a third group (<a href="#CD011564-tbl-0004">Table 3</a>) (<a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>). We thus compared the first two groups together versus the placebo group. One trial with three intervention groups administered 25‐dihydroxyvitamin D in one intervention group, vitamin D<sub>2</sub> in another intervention group, and no intervention in a third group (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>). We compared vitamin D groups together versus the no intervention group. Another trial with three intervention groups administered 1,25‐dihydroxyvitamin D in one intervention group, vitamin D<sub>3</sub> in another intervention group, and placebo in a third group (<a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>). We compared the vitamin D groups together versus the placebo group. </p> <section id="CD011564-sec-0062"> <h6 class="title">Vitamin D<sub>3</sub> (cholecalciferol) </h6> <p>Vitamin D was administered as vitamin D<sub>3</sub> (cholecalciferol) in 20 trials (1592 participants; 44% women; mean age 48 years) (<a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>). Vitamin D<sub>3</sub> was tested orally in 24 trials. Two trials administered vitamin D<sub>3</sub> intramuscularly (<a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>), and one trial administered vitamin D<sub>3</sub> intramuscularly and orally (<a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>). Vitamin D<sub>3</sub> was administered daily in 11 trials (<a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>); weekly in five trials (<a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>); twice a week in one trial (<a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>); in a single dose in two trials (<a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>); and in a single dose and daily in one trial (<a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>). Mean daily dose of vitamin D<sub>3</sub> was 2791 international units (IU). The duration of supplementation in trials using vitamin D<sub>3</sub> was 8 to 48 weeks (mean 24 weeks). The length of the follow‐up period was from 8 to 72 weeks (mean 28 weeks) (<a href="#CD011564-tbl-0004">Table 3</a>). </p> </section> <section id="CD011564-sec-0063"> <h6 class="title">Vitamin D<sub>2</sub> (ergocalciferol) </h6> <p>Vitamin D was administered as vitamin D<sub>2</sub> (ergocalciferol) in three trials (156 participants; 28% women; mean age 54 years) (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>). Vitamin D<sub>2</sub> was tested in a dose of 50,000 IU orally, two or three times weekly for one year in one trial (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>), and 60,000 to 100,000 IU orally weekly in two trials (<a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>). Mean daily dose of vitamin D<sub>2</sub> was 11,429 IU. The duration of supplementation and follow‐up in trials using vitamin D<sub>2</sub> was 6 to 52 weeks (mean 21 weeks). The length of the follow‐up period was from 6 to 52 weeks (mean 21 weeks) (<a href="#CD011564-tbl-0004">Table 3</a>). </p> </section> <section id="CD011564-sec-0064"> <h6 class="title">1,25‐dihydroxyvitamin D (calcitriol)</h6> <p>Vitamin D was administered as 1,25‐dihydroxyvitamin D in four trials (291 participants; 60% women; mean age 52 years) (<a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>). 1,25‐dihydroxyvitamin D was tested singly, orally, and daily in two trials (<a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>). One trial administered 1,25‐dihydroxyvitamin D combined with calcium (<a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>). One trial with a parallel‐group design and three arms tested 1,25‐dihydroxyvitamin D and vitamin D<sub>3</sub> in separate arms (<a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>). The dose of 1,25‐dihydroxyvitamin D was 1.0 μg in two trials (<a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>), and 0.25 μg in two trials (<a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>). Mean daily dose of 1,25‐dihydroxyvitamin D was 0.625 μg. The duration of supplementation and follow‐up in trials using 1,25‐dihydroxyvitamin D was four to 52 weeks (mean 30 weeks) (<a href="#CD011564-tbl-0004">Table 3</a>). </p> </section> <section id="CD011564-sec-0065"> <h6 class="title">25‐hydroxyvitamin D (calcidiol)</h6> <p>Vitamin D was administered as 25‐hydroxyvitamin D in one trial (18 participants; 0% women; mean age 52 years) (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>). 25‐hydroxyvitamin D was tested at a dose of 800 IU/day to 2000 IU/day, orally, for one year (<a href="#CD011564-tbl-0004">Table 3</a>). </p> </section> </section> <section id="CD011564-sec-0066"> <h5 class="title">Control interventions</h5> <p>Twelve trials used a placebo in the control group (<a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>), whilst the remaining 15 trials used no intervention in the control group (<a href="#CD011564-tbl-0002">Table 1</a>) (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>; <a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>). </p> </section> <section id="CD011564-sec-0067"> <h5 class="title">Co‐interventions</h5> <p>Seven trials used pegylated‐interferon and ribavirin combined with vitamin D<sub>3</sub> in the intervention groups versus pegylated‐interferon and ribavirin in the control group (<a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>). One trial used pegylated‐interferon, ribavirin, and simeprevir (direct‐acting antiviral agent) combined with vitamin D<sub>3</sub> in the intervention group versus pegylated‐interferon, ribavirin, and simeprevir in the control group (<a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>). One trial supplemented all participants with vitamin E 400 IU (<a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>). One trial in people with non‐alcoholic fatty liver disease used lifestyle modification (<a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>). </p> </section> <section id="CD011564-sec-0068"> <h5 class="title">Follow‐up</h5> <p>The mean follow‐up period in all 27 trials was 7 months (range 1 to 18 months).</p> </section> </section> <section id="CD011564-sec-0069"> <h4 class="title">Excluded studies</h4> <p>For details of the excluded studies, see <a href="./references#CD011564-sec-0135" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD011564-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed all trials at high risk of bias (had unclear or high risk of bias in one or more domains assessed) (<a href="#CD011564-fig-0002">Figure 2</a>; <a href="#CD011564-fig-0003">Figure 3</a>; <a href="#CD011564-tbl-0002">Table 1</a>). We did not use the test for funnel plot asymmetry because only four trials were included in the meta‐analysis. The adjusted‐rank correlation test (P = 0.34) and a regression asymmetry test (P = 0.48) found no significant evidence of bias. </p> <div class="figure" id="CD011564-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011564-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011564-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011564-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011564-sec-0071"> <h4 class="title">Allocation</h4> <p>Fifteen trials described the generation of allocation sequence adequately (<a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>). The remaining 12 trials were described as being randomised, but the method used for sequence generation was not described or was described insufficiently. </p> <p>Twelve trials described the method used to conceal allocation adequately (<a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>). The remaining 15 trials were described as being randomised, but the method used for allocation concealment was not described or was described insufficiently. </p> </section> <section id="CD011564-sec-0072"> <h4 class="title">Blinding</h4> <p>Eight trials performed and adequately described blinding of participants and personnel (<a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>). Eleven trials did not blind participants and personnel (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>; <a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>), whilst in eight trials the method used for blinding of participants and personnel was not described or was described insufficiently (<a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>). </p> <p>Seven trials performed and adequately described blinding of outcome assessors (<a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>). In the remaining 19 trials the method for blinding of outcome assessors was not described or was described insufficiently. </p> </section> <section id="CD011564-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty trials adequately addressed incomplete outcome data (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>; <a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>). In seven trials information was insufficient to permit an assessment of whether missing data in combination with the method used to handle missing data was likely to induce bias on the effect estimate (<a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>). </p> </section> <section id="CD011564-sec-0074"> <h4 class="title">Selective reporting</h4> <p>Thirteen trials reported the outcomes stated in their respective protocols (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>; <a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>). In 11 trials it was unclear whether all predefined and clinically relevant and reasonably expected outcomes had been reported (<a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>). The authors of three trials did not fully report all predefined outcomes (<a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>). </p> </section> <section id="CD011564-sec-0075"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify any clear signs of academic bias, small‐trial bias, or other potential sources of bias in 13 trials (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>; <a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a>; <a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a>; <a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a>). The remaining 14 trials may or may not have been free of other issues that could put them at risk of bias (<a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a>; <a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a>; <a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>). </p> </section> </section> <section id="CD011564-sec-0076"> <h3 class="title" id="CD011564-sec-0076">Effects of interventions</h3> <p>See: <a href="./full#CD011564-tbl-0001"><b>Summary of findings 1</b> Vitamin D compared with placebo or no intervention for chronic liver diseases in adults</a> </p> <section id="CD011564-sec-0077"> <h4 class="title">Primary outcomes</h4> <section id="CD011564-sec-0078"> <h5 class="title">All‐cause mortality</h5> <p>We are very uncertain about the effect of vitamin D versus placebo or no intervention on all‐cause mortality (risk ratio (RR) 0.86, 95% confidence interval (CI) 0.51 to 1.45; I<sup>2</sup> = 0%; 27 trials; 1979 participants; <a href="./references#CD011564-fig-0008" title="">Analysis 1.1</a>; very low‐certainty evidence). We are very uncertain about the effect of vitamin D versus placebo or no intervention on all‐cause mortality in people with non‐alcoholic fatty liver disease (no data reported; 11 trials; 803 participants); chronic hepatitis C (RR 0.33, 95% CI 0.04 to 3.13; I<sup>2</sup> = 0%; 10 trials; 836 participants); liver cirrhosis (RR 0.91, 95% CI 0.53 to 1.55; I<sup>2</sup> = 0%; 5 trials; 265 participants); or liver transplant recipients (no data reported; 1 trial; 75 participants) (<a href="./references#CD011564-fig-0008" title="">Analysis 1.1</a>; <a href="./full#CD011564-tbl-0001">summary of findings Table 1</a>). The certainty of evidence is very low. The mean follow‐up was 7 months (range 1 to 18 months). </p> <section id="CD011564-sec-0079"> <h6 class="title">Subgroup analysis for overall risk of bias</h6> <p>All trials were at high risk of bias, therefore we did not conduct subgroup analysis.</p> </section> <section id="CD011564-sec-0080"> <h6 class="title">Subgroup analysis for vested interest</h6> <p>Thirteen trials appeared to be free of vested interest. Twelve trials did not provide any information on clinical trial support or sponsorship. Two trials were funded by industry. The test for subgroup differences showed no significant differences in the effect of vitamin D on all‐cause mortality in trials funded by industry (RR 2.69, 95% CI 0.15 to 48.64; 38 participants; 2 trials) and in trials without vested interest (RR 0.83, 95% CI 0.48 to 1.41; I<sup>2</sup> = 0%; 1941 participants; 25 trials) (<a href="./references#CD011564-fig-0009" title="">Analysis 1.2</a>). </p> </section> <section id="CD011564-sec-0081"> <h6 class="title">Subgroup analysis according to vitamin D status at entry</h6> <p>The test for subgroup differences showed insignificant differences in the effect of vitamin D versus placebo or no intervention on all‐cause mortality in participants with normal vitamin D status (RR 0.33, 95% CI 0.04 to 3.13; I<sup>2</sup> = 0%; 8 trials; 549 participants; <a href="./references#CD011564-fig-0010" title="">Analysis 1.3</a>) and with low vitamin D status (RR 0.91, 95% CI 0.53 to 1.55; I<sup>2</sup> = 0%; 19 trials; 1430 participants; <a href="./references#CD011564-fig-0010" title="">Analysis 1.3</a>). </p> </section> <section id="CD011564-sec-0082"> <h6 class="title">Subgroup analysis according to form of vitamin D</h6> <p>The test for subgroup differences showed insignificant differences in the effect of different forms of vitamin D versus placebo or no intervention on all‐cause mortality: vitamin D<sub>3</sub> (RR 0.83, 95% CI 0.48 to 1.41; I<sup>2</sup> = 0%; 20 trials; 1578 participants); vitamin D<sub>2</sub> (RR 3.00, 95% CI 0.15 to 61.74; 1 trial; 150 participants); 25‐hydroxyvitamin D (RR 3.00, 95% CI 0.15 to 61.74; 1 trial; 150 participants); and 1,25 dihydroxyvitamin D (4 zero‐event trials; 291 participants) (<a href="./references#CD011564-fig-0011" title="">Analysis 1.4</a>). </p> </section> <section id="CD011564-sec-0083"> <h6 class="title">Sensitivity analysis for attrition bias</h6> <p>The authors of three trials did not report the exact numbers of participants with missing outcomes in the intervention and control groups (<a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a>; <a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a>; <a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a>). There were no losses to follow‐up in 10 trials (<a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>; <a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a>; <a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a>; <a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a>; <a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a>). In the remaining 14 included trials, the authors reported the exact numbers of participants with missing outcomes in the intervention and control groups. A total of 65/663 (9.8%) participants had missing outcomes in the vitamin D groups versus 65/572 (11.4%) participants in the control groups. </p> </section> <section id="CD011564-sec-0084"> <h6 class="title">Best‐worst‐case scenario sensitivity analysis</h6> <p>When we assumed that all participants lost to follow‐up in the experimental intervention group survived, and all those with missing outcomes in the control group died, vitamin D supplementation significantly decreased mortality (RR 0.14, 95% CI 0.06 to 0.30; P &lt; 0.001; I<sup>2</sup> = 0%; 1737 participants; 24 trials; <a href="./references#CD011564-fig-0012" title="">Analysis 1.5</a>). </p> </section> <section id="CD011564-sec-0085"> <h6 class="title">Worst‐best‐case scenario sensitivity analysis</h6> <p>When we assumed that all participants lost to follow‐up in the experimental intervention group died, and all those with missing outcomes in the control group survived, vitamin D supplementation significantly increased mortality (RR 7.95, 95% CI 3.55 to 17.77; P &lt; 0.001; I<sup>2</sup> = 0%; 1737 participants; 24 trials; <a href="./references#CD011564-fig-0012" title="">Analysis 1.5</a>). </p> </section> <section id="CD011564-sec-0086"> <h6 class="title">Sensitivity analysis for imprecision</h6> <p>Trial Sequential Analysis was performed based on a mortality proportion in the control group of 2%, a relative risk reduction of 20% in the experimental intervention group, a type I error of 1.25%, and type II error of 10% (90% power). There was no diversity. The required information size was 63,116 participants. The cumulative Z‐curve did not cross the trial sequential monitoring boundary for benefit or harm after the 27th trial. The trial sequential monitoring boundary was ignored due to little information use (3.14%) (<a href="#CD011564-fig-0004">Figure 4</a>). We downgraded imprecision two levels with Trial Sequential Analysis for this outcome, which was in agreement with our GRADE assessment. </p> <div class="figure" id="CD011564-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="All‐cause mortality.Trial Sequential Analysis was performed based on a mortality in the control group of 2%, a relative risk reduction of 20% in the experimental intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). There was no diversity. The required information size was 63,116 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundary for benefit or harm after the 27th trial. The trial sequential monitoring boundaries were ignored due to little information (3.14%). The blue line represents the cumulative Z‐score of the meta‐analysis. The green dotted lines represent the conventional statistical boundaries." data-id="CD011564-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>All‐cause mortality.</p> <p>Trial Sequential Analysis was performed based on a mortality in the control group of 2%, a relative risk reduction of 20% in the experimental intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). There was no diversity. The required information size was 63,116 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundary for benefit or harm after the 27th trial. The trial sequential monitoring boundaries were ignored due to little information (3.14%). The blue line represents the cumulative Z‐score of the meta‐analysis. The green dotted lines represent the conventional statistical boundaries. </p> </div> </div> </div> </section> </section> <section id="CD011564-sec-0087"> <h5 class="title">Liver‐related mortality</h5> <p>The evidence of vitamin D versus placebo or no intervention on the effect of vitamin D on liver‐related mortality is very uncertain (RR 1.62, 95% CI 0.08 to 34.66; 1 trial; 18 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0013" title="">Analysis 1.6</a>; <a href="./full#CD011564-tbl-0001">summary of findings Table 1</a>). The follow‐up was 12 months. </p> <section id="CD011564-sec-0088"> <h6 class="title">Subgroup analysis according to vitamin D status at entry</h6> <p>Only one trial including participants with low vitamin D status reported liver‐related mortality, making subgroup analysis impossible. </p> </section> <section id="CD011564-sec-0089"> <h6 class="title">Sensitivity analysis for imprecision</h6> <p>Because of few data, we could not conduct Trial Sequential Analysis, which would only have revealed a similar need to downgrade for imprecision. We downgraded our GRADE assessment two levels for imprecision. </p> </section> </section> <section id="CD011564-sec-0090"> <h5 class="title">Serious adverse events</h5> <p>The evidence of vitamin D (calcitriol) versus placebo or no intervention is very uncertain on the effect of vitamin D on the risk of hypercalcaemia (RR 5.00, 95% CI 0.25 to 100.8; 1 trial; 76 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0014" title="">Analysis 1.7</a>); myocardial infarction (RR 0.75, 95% CI 0.08 to 6.81; 2 trials; 86 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0014" title="">Analysis 1.7</a>); thyroiditis (RR 0.33, 95% CI 0.01 to 7.91; 1 trial; 68 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0014" title="">Analysis 1.7</a>); circular haemorrhoidal prolapse (RR 3.00, 95% CI 0.14 to 65.90; 1 trial; 20 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0014" title="">Analysis 1.7</a>); and bronchopneumonia (RR 0.33, 95% CI 0.02 to 7.32; 1 trial; 20 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0014" title="">Analysis 1.7</a>; <a href="./full#CD011564-tbl-0001">summary of findings Table 1</a>). The mean follow‐up was 10.5 months. </p> <section id="CD011564-sec-0091"> <h6 class="title">Sensitivity analysis for imprecision</h6> <p>Because of few data, we could not conduct Trial Sequential Analysis, which would only have revealed a similar need to downgrade imprecision. We downgraded our GRADE assessment two levels for imprecision. </p> </section> </section> </section> <section id="CD011564-sec-0092"> <h4 class="title">Secondary outcomes</h4> <section id="CD011564-sec-0093"> <h5 class="title">Liver‐related morbidity</h5> <p>We found no data on liver‐related morbidity.</p> </section> <section id="CD011564-sec-0094"> <h5 class="title">Health‐related quality of life</h5> <p>We found no data on health‐related quality of life.</p> </section> <section id="CD011564-sec-0095"> <h5 class="title">Non‐serious adverse events</h5> <p>The evidence is very uncertain as to whether vitamin D<sub>3</sub> increases or decreases the risks of glossitis (RR 3.70, 95% CI 0.16 to 87.58; 1 trial; 65 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); depression (RR 3.00, 95% CI 0.14 to 65.90; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); lower back pain (RR 3.00, 95% CI 0.14 to 65.90; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); abdominal bloating (RR 0.33, 95% CI 0.02 to 7.32; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); cold (RR 0.33, 95% CI 0.02 to 7.32; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); constipation (RR 0.33, 95% CI 0.02 to 7.32; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); sore throat (RR 0.33, 95% CI 0.02 to 7.32; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); sour taste in mouth (RR 0.33, 95% CI 0.02 to 7.32; one trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); contused lacerated wound (RR 0.33, 95% CI 0.02 to 7.32; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); multiple white matter lesions (RR 0.33, 95% CI 0.02 to 7.32; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); gastro‐oesophageal reflux (RR 3.00, 95% CI 0.14 to 65.90; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); abdominal menstrual cramps (RR 3.00, 95% CI 0.14 to 65.90; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); tubular colon adenoma (RR 3.00, 95% CI 0.14 to 65.90; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); gastric motility disturbance (RR 3.00, 95% CI 0.14 to 65.90; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); irritable bowel syndrome (RR 5.00, 95% CI 0.27 to 92.62; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); knee pain (RR 3.00, 95% CI 0.14 to 65.90; 1 trial; 20 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>); and severe allergy (RR 5.09, 95% CI 0.25 to 103.64; 1 trial; 109 participants; <a href="./references#CD011564-fig-0017" title="">Analysis 1.10</a>) due to the overall rating of very low certainty of evidence (<a href="./full#CD011564-tbl-0001">summary of findings Table 1</a>). The mean follow‐up was seven months. </p> <p>Several non‐serious adverse events were reported in people with chronic hepatitis C treated with a combination of vitamin D and pegylated‐interferon and ribavirin. These were similar in both vitamin D and control groups and consistent with typical interferon‐ribavirin‐induced systemic symptoms such as nausea, headache, insomnia, chills, myalgia, pyrexia, pruritus, mild neutropenia, mild thrombocytopenia, mild neutropenia, and mild anaemia (<a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a>; <a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a>; <a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a>; <a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a>; <a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a>; <a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a>; <a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a>). </p> </section> <section id="CD011564-sec-0096"> <h5 class="title">Failure of virological response</h5> <section id="CD011564-sec-0097"> <h6 class="title">Failure of rapid virological response (at week four) in people with chronic viral hepatitis C </h6> <p>Vitamin D<sub>3</sub> versus placebo may increase or have no effect on rapid virological response in people with chronic hepatitis C, but the evidence is very uncertain (RR 0.75, 95% CI 0.60 to 0.95; P = 0.02; I<sup>2</sup> = 0%; 3 trials; 247 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0018" title="">Analysis 1.11</a>). The mean follow‐up was 16 months. </p> </section> <section id="CD011564-sec-0098"> <h6 class="title">Sensitivity analysis for imprecision</h6> <p>Trial Sequential Analysis was conducted based on a failure of rapid virological response in the control group of 53%, a relative risk reduction (RRR) of 20% in the intervention group, a type I error of 1.25%, and type II error of 10% (90% power). There was no diversity. The required information size was 1269 participants. The cumulative Z‐curve crossed the conventional monitoring boundary for benefit, but did not cross the trial sequential monitoring boundaries for benefit, futility or harm (<a href="#CD011564-fig-0005">Figure 5</a>). We downgraded imprecision two levels with Trial Sequential Analysis, for this outcome, which was in agreement with our GRADE assessment. </p> <div class="figure" id="CD011564-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Rapid virological response.Trial Sequential Analysis was performed based on a failure of rapid virological response in the control group of 53%, a relative risk reduction (RRR) of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). There was no diversity. The required information size was 1269 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit but did not cross the trial sequential monitoring boundary for benefit (red down‐sloping line). The blue line represents the cumulative Z‐score of the meta‐analysis. The green dotted lines represent the conventional statistical boundaries. The red inward‐sloping lines represent the trial sequential monitoring boundaries." data-id="CD011564-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Rapid virological response.</p> <p>Trial Sequential Analysis was performed based on a failure of rapid virological response in the control group of 53%, a relative risk reduction (RRR) of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). There was no diversity. The required information size was 1269 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit but did not cross the trial sequential monitoring boundary for benefit (red down‐sloping line). The blue line represents the cumulative Z‐score of the meta‐analysis. The green dotted lines represent the conventional statistical boundaries. The red inward‐sloping lines represent the trial sequential monitoring boundaries. </p> </div> </div> </div> </section> </section> <section id="CD011564-sec-0099"> <h5 class="title">Failure of early virological response (at week 12) in people with chronic viral hepatitis C </h5> <p>Vitamin D<sub>3</sub> versus placebo may increase or have no effect on early virological response in people with chronic hepatitis C, but the evidence is very uncertain (RR 0.33, 95% CI 0.11 to 1.00; P = 0.05; I<sup>2</sup>= 75%; 4 trials; 315 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0019" title="">Analysis 1.12</a>). The mean follow‐up was 13 months. </p> <section id="CD011564-sec-0100"> <h6 class="title">Sensitivity analysis for imprecision</h6> <p>Trial Sequential Analysis was performed based on a failure of early virological response in the control group of 34%, a relative risk reduction of 20% in the intervention group, a type I error of 1.25%, and type II error of 10% (90% power). The diversity was 88%. The required information size was 21,306 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit. The trial sequential monitoring boundary was ignored because of little information use (1.48%) (<a href="#CD011564-fig-0006">Figure 6</a>). We downgraded two levels for imprecision with Trial Sequential Analysis for this outcome, which was in agreement with our GRADE assessment. </p> <div class="figure" id="CD011564-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Early virological response.Trial Sequential Analysis was performed based on failure of early virological response in the control group of 34%, a relative risk reduction of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). The diversity was 88%. The required information size was 21,306 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit. The trial sequential monitoring boundary was ignored due to little information (1.48%). The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries." data-id="CD011564-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Early virological response.</p> <p>Trial Sequential Analysis was performed based on failure of early virological response in the control group of 34%, a relative risk reduction of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). The diversity was 88%. The required information size was 21,306 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit. The trial sequential monitoring boundary was ignored due to little information (1.48%). The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries. </p> </div> </div> </div> </section> </section> <section id="CD011564-sec-0101"> <h5 class="title">Failure of sustained virological response (at six months after treatment) in people with chronic viral hepatitis C </h5> <p>Vitamin D<sub>3</sub> may increase or have no effect on sustained virological response in people with chronic hepatitis C, but the evidence is very uncertain (RR 0.65, 95% CI 0.42 to 1.01; I<sup>2</sup> = 76%; 7 trials; 630 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0020" title="">Analysis 1.13</a>; <a href="./full#CD011564-tbl-0001">summary of findings Table 1</a>). The mean follow‐up was 16 months. </p> <section id="CD011564-sec-0102"> <h6 class="title">Sensitivity analysis for imprecision</h6> <p>Trial Sequential Analysis was performed based on a failure of sustained virological response in the control group of 48%, a relative risk reduction of 20% in the intervention group, a type I error of 1.25%, and type II error of 10% (90% power). The diversity was 80%. The required information size was 7570 participants (<a href="#CD011564-fig-0007">Figure 7</a>). We downgraded two levels for imprecision with Trial Sequential Analysis for this outcome, which was in agreement with our GRADE assessment. </p> <div class="figure" id="CD011564-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Sustained virological response.Trial Sequential Analysis was performed based on failure of sustained virological response in the control group of 48%, a relative risk reduction (RRR) of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). Diversity was 80%. The required information size was 7570 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit. However, it did not cross any of the monitoring boundaries for benefit, harm, or futility. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries. The red inward‐sloping lines represent the trial sequential monitoring boundaries for benefit and harm." data-id="CD011564-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sustained virological response.</p> <p>Trial Sequential Analysis was performed based on failure of sustained virological response in the control group of 48%, a relative risk reduction (RRR) of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). Diversity was 80%. The required information size was 7570 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit. However, it did not cross any of the monitoring boundaries for benefit, harm, or futility. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries. The red inward‐sloping lines represent the trial sequential monitoring boundaries for benefit and harm. </p> </div> </div> </div> </section> </section> <section id="CD011564-sec-0103"> <h5 class="title">Acute cellular rejection in liver transplant recipients</h5> <p>The evidence is very uncertain on the effect of 1,25‐dihydroxyvitamin D on acute cellular rejection in liver transplant recipients, which may decrease or increase (RR 0.33, 95% CI 0.04 to 2.62; 1 trial; 75 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0021" title="">Analysis 1.14</a>). The follow‐up was one week. </p> </section> <section id="CD011564-sec-0104"> <h5 class="title">Vitamin D status</h5> <p>Vitamin D supplementation versus placebo seems to increase vitamin D status of participants, but the evidence is very uncertain (MD 18.49 ng/mL, 95% CI 14.52 to 22.47; I<sup>2</sup> = 93%; 15 trials; 1078 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0022" title="">Analysis 1.15</a>). The mean follow‐up was six months. </p> </section> <section id="CD011564-sec-0105"> <h5 class="title">Bone mineral density</h5> <p>Vitamin D seems to show an effect on bone mineral density in people with alcoholic liver cirrhosis, but the evidence is very uncertain (MD 0.15 ng/mL, 95% CI 0.04 to 0.26; 1 trial; 18 participants; very low‐certainty evidence; <a href="./references#CD011564-fig-0023" title="">Analysis 1.16</a>). Follow‐up was 12 months (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>). Two other trials reported bone mineral density, but we could not use the data in analysis (<a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a>; <a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a>). </p> </section> <section id="CD011564-sec-0106"> <h5 class="title">Biochemical indices</h5> <section id="CD011564-sec-0107"> <h6 class="title">Worse prognosis if value result is higher than the normal range</h6> <p>The evidence is very uncertain on the effect of vitamin D on serum activity of aspartate aminotransferase (MD ‐1.75 IU/L, 95% CI ‐5.41 to 1.91; I<sup>2</sup> = 82%; 12 trials; 774 participants; <a href="./references#CD011564-fig-0024" title="">Analysis 1.17</a>); serum activity of alanine aminotransferase (MD ‐2.30 IU/L, 95% CI ‐7.60 to 3.00; I<sup>2</sup> = 86%; 13 trials; 855 participants; <a href="./references#CD011564-fig-0025" title="">Analysis 1.18</a>); serum activity of alkaline phosphatases (MD ‐0.95 IU/L, 95% CI ‐15.10 to 13.20; I<sup>2</sup> = 52%; 6 trials; 344 participants; <a href="./references#CD011564-fig-0026" title="">Analysis 1.19</a>); serum activity of gamma‐glutamyl transpeptidase (MD ‐2.69 IU/L, 95% CI ‐5.26 to ‐0.11; I<sup>2</sup> = 0%; 4 trials; 227 participants; <a href="./references#CD011564-fig-0027" title="">Analysis 1.20</a>); serum concentration of bilirubin (MD 0.32 mg/dL, 95% CI 0.00 to 0.63; I<sup>2</sup> = 29%; 3 trials; 74 participants; <a href="./references#CD011564-fig-0028" title="">Analysis 1.21</a>); serum concentration of triglyceride (MD 11.27 mg/dL, 95% CI ‐10.99 to 33.53; I<sup>2</sup> = 87%; 5 trials; 460 participants; <a href="./references#CD011564-fig-0029" title="">Analysis 1.22</a>); serum concentration of cholesterol (MD 3.51 mg/dL, 95% CI ‐2.83 to 9.85; I<sup>2</sup> = 0%; 4 trials; 400 participants; <a href="./references#CD011564-fig-0030" title="">Analysis 1.23</a>); and serum concentration of low‐density lipoprotein (LDL) cholesterol (MD ‐0.97 mg/dL, 95% CI ‐8.70 to 6.76; I<sup>2</sup> = 60%; 4 trials; 400 participants; <a href="./references#CD011564-fig-0031" title="">Analysis 1.24</a>). </p> </section> <section id="CD011564-sec-0108"> <h6 class="title">Worse prognosis if value result is lower than the normal range</h6> <p>The evidence is very uncertain on the effect of vitamin D on serum concentration of albumin (MD ‐1.18 g/L, 95% CI ‐2.96 to 0.59; I<sup>2</sup> = 0%; 3 trials; 74 participants; <a href="./references#CD011564-fig-0032" title="">Analysis 1.25</a>) and serum concentration of high‐density lipoprotein (HDL) cholesterol (MD 1.14 mg/dL, 95% CI ‐0.64 to 2.92; I<sup>2</sup> = 0%; 4 trials; 400 participants; <a href="./references#CD011564-fig-0033" title="">Analysis 1.26</a>). </p> </section> <section id="CD011564-sec-0109"> <h6 class="title">Worse prognosis if value result is lower or higher than the normal range</h6> <p>The evidence is very uncertain on the effect of vitamin D on serum concentration of calcium (MD 0.04 mg/dL, 95% CI ‐0.12 to 0.19; I<sup>2</sup> = 46%; 7 trials; 423 participants; <a href="./references#CD011564-fig-0034" title="">Analysis 1.27</a>); serum concentration of glucose (MD 1.44 mg/dL, 95% CI ‐5.05 to 7.94; I<sup>2</sup> = 85%; 6 trials; 469 participants; <a href="./references#CD011564-fig-0035" title="">Analysis 1.28</a>); serum concentration of phosphorus (MD 0.17 mg/dL, 95% CI ‐0.16 to 0.50; I<sup>2</sup> = 53%; 4 trials; 307 participants; <a href="./references#CD011564-fig-0036" title="">Analysis 1.29</a>); serum concentration of adiponectin (MD 1.02 µg/mL, 95% CI ‐0.27 to 2.30; I<sup>2</sup> = 62%; 4 trials; 276 participants; <a href="./references#CD011564-fig-0037" title="">Analysis 1.30</a>); serum concentration of insulin (MD 0.03 mIU/mL, 95% CI ‐1.15 to 1.21; I<sup>2</sup> = 0%; 6 trials; 428 participants; <a href="./references#CD011564-fig-0038" title="">Analysis 1.31</a>); serum concentration of parathyroid hormone (MD ‐15.18 pg/mL, 95% CI ‐38.54 to 8.18, 2 trials; 118 participants; <a href="./references#CD011564-fig-0039" title="">Analysis 1.32</a>); and serum concentration of C‐reactive protein (MD ‐0.50 mg/L, 95% CI ‐0.93 to ‐0.07; I<sup>2</sup> = 86%; 4 trials; 254 participants; <a href="./references#CD011564-fig-0040" title="">Analysis 1.33</a>). </p> </section> </section> </section> <section id="CD011564-sec-0110"> <h4 class="title">Summary of findings</h4> <p>We have presented our findings for the following outcomes in <a href="./full#CD011564-tbl-0001">summary of findings Table 1</a>: all‐cause mortality (mean follow‐up of nine months); liver‐related mortality (mean follow‐up of 12 months); serious adverse events (mean follow‐up of 10.5 months); liver‐related morbidity (no trials); health‐related quality of life (no trials); non‐serious adverse events (mean follow‐up of seven months); failure of sustained virological response (mean follow‐up of 16 months). We downgraded the certainty of the evidence for the outcomes for which data were available to very low. For the outcomes all‐cause mortality, liver‐related mortality, serious adverse events, and non‐serious adverse events, we downgraded the evidence because of risk of bias and imprecision; and for sustained virological response, we downgraded the evidence because of risk of bias, imprecision, inconsistency, and indirectness. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011564-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011564-sec-0111"></div> <section id="CD011564-sec-0112"> <h3 class="title" id="CD011564-sec-0112">Summary of main results</h3> <p>Compared to the previous version of this review (<a href="./references#CD011564-bbs2-0224" title="BjelakovicG , NikolovaD , BjelakovicM , GluudC . Vitamin D supplementation for chronic liver diseases in adults. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD011564. [DOI: 10.1002/14651858.CD011564.pub2]">Bjelakovic 2017</a>), the number of trials included in the current review has expanded with the addition of 12 new trials (44%), adding another 945 participants (48%). The current review thus includes 27 randomised clinical trials with 1979 participants. However, our results remain largely the same. The evidence is very uncertain regarding the effect of vitamin D supplements in the form of vitamin D<sub>3</sub>, vitamin D<sub>2</sub>, 1,25‐dihydroxyvitamin D, or 25‐dihydroxyvitamin D on all‐cause mortality, liver‐related mortality, and serious and non‐serious adverse events in people with chronic liver diseases. The trials did not present data on liver‐related morbidity such as gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, ascites, or liver cancer. There were no data on health‐related quality of life. It is very uncertain if vitamin D increases the number of people with sustained virological response or decreases the number of people with acute cellular rejection in liver transplant recipients. Analyses of three trials in people with chronic hepatitis C suggested that vitamin D<sub>3</sub> might be beneficial in increasing the number of people with rapid virological response, but the evidence is very uncertain. Vitamin D status of participants with chronic liver diseases seems to increase after supplementation with vitamin D. Vitamin D may or may not have an effect on biochemical indices, but the evidence for all biochemical indices is very uncertain. </p> <p>The results of our systematic review should be interpreted with great caution because all the included trials were assessed at high risk of bias. The number of people and the trials that provided outcome data were insufficient, which adds to the risk of both type I and type II errors (<a href="./references#CD011564-bbs2-0143" title="KeusF , WetterslevJ , GluudC , Van LaarhovenCJ . Evidence at a glance: error matrix approach for overviewing available evidence. BMC Medical Research Methodology2010;10:90.">Keus 2010</a>; <a href="./references#CD011564-bbs2-0217" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>). Our sensitivity analysis with Trial Sequential Analysis revealed that there was insufficient information to reach robust conclusions. In this second edition of our review, we defined what the minimal relevant difference for our continuous outcome would be if data are published. Moreover, type 1 and 2 values, diversity, control group proportions, and plausible relative risk reduction will all affect the DARIS calculated, especially as these have changed since the previous version of the review. This is in order to control risks of type 1 and type 2 errors, but will increase the requirement for trial participants. The latter may be seen as an obstacle by many. </p> <p>Although vitamin D deficiency is considered to be common in people with chronic liver diseases (<a href="./references#CD011564-bbs2-0075" title="ChenEQ , ShiY , TangH . New insight of vitamin D in chronic liver diseases. Hepatobiliary &amp; Pancreatic Diseases International2014;13(6):580-5.">Chen 2014</a>; <a href="./references#CD011564-bbs2-0137" title="IruzubietaP , Terán Á, CrespoJ , FábregaE . Vitamin D deficiency in chronic liver disease. World Journal of Hepatology2014;6(12):901-15.">Iruzubieta 2014</a>; <a href="./references#CD011564-bbs2-0087" title="ElangovanH , ChahalS , GuntonJE . Vitamin D in liver disease: current evidence and potential directions. Biochimica et Biophysica Acta2017;1863(4):907-16.">Elangovan 2017</a>), we found no convincing evidence that vitamin D supplementation might have therapeutic impact in these individuals; however, as highlighted, the evidence is very uncertain. </p> </section> <section id="CD011564-sec-0113"> <h3 class="title" id="CD011564-sec-0113">Overall completeness and applicability of evidence</h3> <p>We included all eligible randomised clinical trials up to November 2020. We found a large number of randomised trials with a small number of participants. We found significant statistical heterogeneity in some of our analyses, such as biochemical indices. This decreases the precision and power of our analyses (<a href="./references#CD011564-bbs2-0209" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLOS ONE2013;8(3):e59202.">Turner 2013</a>; <a href="./references#CD011564-bbs2-0126" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). Our analyses revealed that outcome reporting was missing in approximately 10% of trial participants. Accordingly, our 'best‐worst‐case' and 'worst‐best‐case' analyses on all‐cause mortality revealed that our results were compatible with both a large beneficial effect and a large detrimental effect of vitamin D. Although these extreme sensitivity analyses are unlikely scenarios, they reveal how missing numbers of participants can substantially change findings from showing great benefit into showing a null effect, or possibly even a harmful effect. We therefore advise critical evaluation of the evidence. </p> </section> <section id="CD011564-sec-0114"> <h3 class="title" id="CD011564-sec-0114">Quality of the evidence</h3> <p>This review followed the overall plan of our published, peer‐reviewed Cochrane protocol (<a href="./references#CD011564-bbs2-0223" title="BjelakovicG , NikolovaD , BjelakovicM , GluudC . Vitamin D supplementation for chronic liver diseases in adults. Cochrane Database of Systematic Reviews2015, Issue 3. Art. No: CD011564. [DOI: 10.1002/14651858.CD011564]">Bjelakovic 2015</a>), some parts of which we revised to enhance clarity for the reader (See <a href="#CD011564-sec-0131">Differences between protocol and review</a>). We conducted a thorough review in accordance with Cochrane methodology (<a href="./references#CD011564-bbs2-0125" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>; <a href="./references#CD011564-bbs2-0126" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>), and implemented findings of methodological studies (<a href="./references#CD011564-bbs2-0188" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD011564-bbs2-0169" title="MoherD , PhamB , JonesA , CookDJ , JadadA , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD011564-bbs2-0147" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>; <a href="./references#CD011564-bbs2-0219" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601-5.">Wood 2008</a>; <a href="./references#CD011564-bbs2-0182" title="SavovićJ , JonesH , AltmanD , HarrisR , JűniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment2012;16(35):1-82.">Savović 2012a</a>; <a href="./references#CD011564-bbs2-0183" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savović 2012b</a>; <a href="./references#CD011564-bbs2-0160" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3]">Lundh 2017</a>; <a href="./references#CD011564-bbs2-0184" title="SavovićJ , AklEA , HróbjartssonA . Financial conflicts of interest in clinical research. Intensive Care Medicine2018;44(10):1767-9.">Savović 2018a</a>). </p> <p>We repeatedly searched several databases and contacted authors of trials and industry producing vitamin D supplements, therefore we believe it is unlikely that we have overlooked important randomised clinical trials. As stated below, we may have missed trials only reported to regulatory authorities. However, such trials are often neutral or negative (<a href="./references#CD011564-bbs2-0187" title="SchrollJB , BeroL , GøtzschePC . Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ (Clinical Research Ed.)2013;346:f2231.">Schroll 2013</a>). We found no evidence of publication bias (<a href="./references#CD011564-bbs2-0141" title="JohnsonRT , DickersinK . Publication bias against negative results from clinical trials: three of the seven deadly sins. Nature Clinical Practice. Neurology2007;3(11):590-1.">Johnson 2007</a>). However, only about every second trial is reported (<a href="./references#CD011564-bbs2-0100" title="GluudC , HildenJ . Povl Heiberg's 1897 methodological study on the statistical method as an aid in therapeutic trials, 2008. www.jameslindlibrary.org/articles/povl-heibergs-1897-methodological-study-on-the-statistical-method-as-an-aid-in-therapeutic-trials/ (accessed 17 July 2017).">Gluud 2008</a>), so we cannot exclude reporting biases. </p> <p>We used <a href="./references#CD011564-bbs2-0101" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 4 November 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a> to construct a summary of findings table (<a href="./full#CD011564-tbl-0001">summary of findings Table 1</a>) (<a href="./references#CD011564-bbs2-0101" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 4 November 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). We calculated the optimal information size when rating imprecision with Trial Sequential Analysis. The GRADE assessments showed that the certainty of evidence was very low for all‐cause mortality, liver‐related mortality, serious adverse events (hypercalcaemia, myocardial infarction, thyroiditis, circular haemorrhoidal prolapse, and bronchopneumonia), liver‐related morbidity, health‐related quality of life, non‐serious adverse events, and failure of sustained virological response. All included trials were at high risk of bias. </p> <p>In some of our analyses (i.e. biochemical indices) heterogeneity was substantial. This was due to the fact that biochemical indices were measured in people with different aetiology of chronic liver diseases. We also assessed the certainty of the evidence using the GRADE approach based on risk of attrition bias for imprecision, significant between‐trial heterogeneity for inconsistency, and design errors for indirectness. We also conducted Trial Sequential Analysis based on the estimation of the DARIS to avoid an undue risk of random errors in a cumulative meta‐analysis and to prevent premature statements of superiority of vitamin D or of lack of effect (<a href="./references#CD011564-bbs2-0070" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology2008;61(8):763-9.">Brok 2008</a>; <a href="./references#CD011564-bbs2-0215" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>; <a href="./references#CD011564-bbs2-0071" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology2009;38(1):287-98.">Brok 2009</a>; <a href="./references#CD011564-bbs2-0203" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology2009;38(1):276-86.">Thorlund 2009</a>; <a href="./references#CD011564-bbs2-0216" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>; <a href="./references#CD011564-bbs2-0204" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PLOS ONE2011;6(10):e25491.">Thorlund 2011</a>; <a href="./references#CD011564-bbs2-0205" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/wp-content/uploads/2020/12/tsa_manual_ENG.pdf 2017 (accessed 2 September 2020).">Thorlund 2017</a>; <a href="./references#CD011564-bbs2-0207" title="Copenhagen Trial UnitTrial Sequential Analysis. Copenhagen Trial Unit, Version 0.9.5.10 Beta. Copenhagen: Copenhagen Trial Unit, 2017. ctu.dk/tsa/downloads/.">TSA 2017</a>; <a href="./references#CD011564-bbs2-0217" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>). We compared the results of imprecision with GRADE and with Trial Sequential Analysis. The results did not differ, which supports previous studies (<a href="./references#CD011564-bbs2-0073" title="CastelliniG , BruschettiniM , GianolaS , GluudC , MojaL . Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and Trial Sequential Analysis. Systematic Reviews2018;7(1):110.">Castellini 2018</a>; <a href="./references#CD011564-bbs2-0096" title="GartlehnerG , Nussbaumer-StreitB , WagnerG , PatelS , Swinson-EvansT , DobrescuA , et al. Increased risks for random errors are common in outcomes graded as high certainty of evidence. Journal of Clinical Epidemiology2019;106:50-9.">Gartlehner 2019</a>). </p> </section> <section id="CD011564-sec-0115"> <h3 class="title" id="CD011564-sec-0115">Potential biases in the review process</h3> <p>Certain limitations of this review warrant consideration. As with all systematic reviews, our findings and interpretations are limited by the certainty and quantity of the available evidence on the effects of vitamin D on chronic liver diseases. Despite extensive speculations in the literature and a number of epidemiological studies that claimed possible beneficial effects of vitamin D in people with chronic liver diseases, only a few randomised clinical trials assessed such effects. The duration of supplementation and duration of follow‐up were short in some included trials, which may make it difficult to detect any effects, beneficial or harmful. We assessed all 27 included trials at high risk of bias. Instead of reporting clinical outcomes, most of the trials based their analyses on surrogate outcomes. Such outcomes may be clinically meaningless if they have not been properly validated against clinical outcomes (<a href="./references#CD011564-bbs2-0099" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734-42.">Gluud 2007</a>; <a href="./references#CD011564-bbs2-0139" title="JakobsenJC , NielsenEE , FeinbergJ , KatakamKK , FobianK , HauserG , et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews2017, Issue 9. Art. No: CD012143. [DOI: 10.1002/14651858.CD012143.pub3]">Jakobsen 2017</a>). Many of the included trials were not adequately powered. These factors corrupt the validity of our results (<a href="./references#CD011564-bbs2-0188" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD011564-bbs2-0169" title="MoherD , PhamB , JonesA , CookDJ , JadadA , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD011564-bbs2-0147" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>; <a href="./references#CD011564-bbs2-0219" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601-5.">Wood 2008</a>; <a href="./references#CD011564-bbs2-0182" title="SavovićJ , JonesH , AltmanD , HarrisR , JűniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment2012;16(35):1-82.">Savović 2012a</a>; <a href="./references#CD011564-bbs2-0183" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savović 2012b</a>). Adverse events were insufficiently reported. It has been noted that adverse events are very often neglected in randomised trials (<a href="./references#CD011564-bbs2-0135" title="IoannidisJP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine2009;169(19):1737-9.">Ioannidis 2009</a>). In a number of trials in people with chronic hepatitis C, vitamin D was administered in combination with pegylated‐interferon and ribavirin, which made it difficult to judge the beneficial or harmful effects of vitamin D, or to judge which intervention one should assign any of the observed adverse events. Significant between‐trial heterogeneity was present in some of our meta‐analyses. This may emphasise the inconsistency of our findings and may additionally question some of these findings. </p> <p>Most of the included trials used vitamin D<sub>3</sub>; three trials tested vitamin D<sub>2</sub>; four trials tested 1,25‐dihydroxyvitamin D; and one trial tested 25‐dihydroxyvitamin D. </p> <p>We did not search the files of regulatory agencies such as the US Food and Drug Administration and European Medicines Agency, which may have biased our selection of trials (<a href="./references#CD011564-bbs2-0187" title="SchrollJB , BeroL , GøtzschePC . Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ (Clinical Research Ed.)2013;346:f2231.">Schroll 2013</a>; <a href="./references#CD011564-bbs2-0065" title="BoesenK . Methodological Limitations of Psychiatric Drug Trials with a Particular Focus on Extended-Release Methylphenidate (Metodebegraensninger i Psykiatriske Laegemiddelforsøg Med et Saerligt Fokus på Methylphenidat Depotpraeparater) [PhD thesis]. University of Copenhagen, 2020.">Boesen 2021</a>). We did not conduct searches for observational studies on harms, which may have biased our findings towards benefits of the interventions with our less focus on harms (<a href="./references#CD011564-bbs2-0200" title="StorebøOJ , KroghHB , RamstadE , Moreira-MaiaCR , HolmskovM , SkoogM , et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ (Clinical Research Ed.)2015;351:h5203.">Storebø 2015</a>; <a href="./references#CD011564-bbs2-0201" title="StorebøOJ , PedersenN , RamstadE , KielsholmML , NielsenSS , KroghHB , et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomised studies. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD012069. [DOI: 10.1002/14651858.CD012069.pub2]">Storebø 2018</a>). </p> <p>Different types of bias could have influenced the results of our meta‐analyses including selective reporting of some results in trial publications (<a href="./references#CD011564-bbs2-0074" title="ChanAW , HróbjartssonA , HaahrMT , GøtzschePC , AltmanDG . Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA2004;291(20):2457-65.">Chan 2004</a>; <a href="./references#CD011564-bbs2-0218" title="WilliamsonPR , GambleC , AltmanDG , HuttonJL . Outcome selection bias in meta-analysis. Statistical Methods in Medical Research2005;14(5):515-24.">Williamson 2005</a>; <a href="./references#CD011564-bbs2-0094" title="FurukawaTA , WatanabeN , OmoriIM , MontoriVM , GuyattGH . Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA2007;297(5):468-70.">Furukawa 2007</a>). Outcome reporting in the included trials was insufficient and inconsistent. There are several possible explanations for selective reporting of outcomes in randomised clinical trials. Trials in which the outcome was not reported may not have measured our outcomes of interest. Researchers may not have reported unexpected results or results may have not satisfied sponsors (<a href="./references#CD011564-bbs2-0153" title="LesserLI , EbbelingCB , GooznerM , WypijD , LudwigDS . Relationship between funding source and conclusion among nutrition-related scientific articles. PLOS Medicine2007;4(1):e5.">Lesser 2007</a>). Pharmaceutical companies provided vitamin D in two of the 27 included trials. This number may in actuality be higher because this information was not available in 11 trials. It could be that researchers have selectively reported outcomes, which may also allude to a publication bias. We are well aware of the difficulties in collecting data on outcomes in clinical trials that focus on safety and efficacy evaluations. The worst result of outcome reporting bias and suppression of some significant or non‐significant findings could be the use of harmful interventions. The results of meta‐analyses may underestimate the true effects of interventions when there is exaggerated outcome reporting bias. One would wish that the results of randomised clinical trials were reported in greater detail (<a href="./references#CD011564-bbs2-0173" title="Nordic Trial Alliance Working Group on Transparency and Registration. Transparency and registration in clinical research in the Nordic countries. nta.nordforsk.org/projects/nta_transparency_report.pdf (accessed 6 November 2020).">Nordic Trial Alliance 2015</a>). In some of the trials, instead of full reporting, we found partial or qualitative reporting. The huge human efforts of investigators and the high cost of randomised clinical trials should be justified with more rigour in their reporting. In spite of the large investment in the reviewed trials, a number of questions remain unanswered. </p> <p>Other types of bias, such as academic bias, bias from trials with deficiencies in the trial design (<a href="./references#CD011564-bbs2-0188" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD011564-bbs2-0169" title="MoherD , PhamB , JonesA , CookDJ , JadadA , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD011564-bbs2-0147" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>), and small‐trial bias, <a href="./references#CD011564-bbs2-0193" title="SiersmaV , Als-NielsenB , ChenW , HildenJ , GluudLL , GluudC . Multivariable modelling for meta-epidemiological assessment of the association between trial quality and treatment effects estimated in randomized clinical trials. Statistics in Medicine2007;26(14):2745-58.">Siersma 2007</a>, could possibly have influenced our results. Meta‐analysis of randomised trials increases the power and precision of the estimated intervention effect, but this effect may be influenced by systematic errors or random errors and can lead to a report of false significant results (<a href="./references#CD011564-bbs2-0098" title="GluudC . The culture of designing hepato-biliary randomised trials. Journal of Hepatology2006;44(3):607-15. [MEDLINE: 16434120]">Gluud 2006</a>; <a href="./references#CD011564-bbs2-0215" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>). It is probable that the results of our meta‐analysis were influenced by random errors and systematic errors. </p> <p>A number of design errors may have influenced our results, the first of which is abuse of surrogate outcomes. In most of the included trials, study authors used non‐validated surrogate outcomes such as biochemical indices and liver steatosis, assuming that normal levels are beneficial. The ideal primary outcome in a randomised clinical trial is the outcome relevant to the person's quality of life or course of disease. Relying on non‐validated potential surrogate outcomes is potentially dangerous when assessing new therapies (<a href="./references#CD011564-bbs2-0099" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734-42.">Gluud 2007</a>; <a href="./references#CD011564-bbs2-0095" title="GarattiniS , JakobsenJC , WetterslevJ , BerteléV , BanziR , RathA , et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13-21.">Garattini 2016</a>). We lack validated surrogate outcome measures in hepatology. Some trials included in this review examined early, rapid, or sustained virological response as a surrogate outcome for successful treatment. However, improved early, rapid, or sustained virological response does not definitively mean significant improvement in clinical outcomes (<a href="./references#CD011564-bbs2-0099" title="GluudC , BrokJ , GongY , KoretzRL . Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology2007;46(4):734-42.">Gluud 2007</a>; <a href="./references#CD011564-bbs2-0139" title="JakobsenJC , NielsenEE , FeinbergJ , KatakamKK , FobianK , HauserG , et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews2017, Issue 9. Art. No: CD012143. [DOI: 10.1002/14651858.CD012143.pub3]">Jakobsen 2017</a>). The use of new interventions in hepatology should not be justified unless these have been confirmed beneficial on clinical outcomes (<a href="./references#CD011564-bbs2-0098" title="GluudC . The culture of designing hepato-biliary randomised trials. Journal of Hepatology2006;44(3):607-15. [MEDLINE: 16434120]">Gluud 2006</a>; <a href="./references#CD011564-bbs2-0139" title="JakobsenJC , NielsenEE , FeinbergJ , KatakamKK , FobianK , HauserG , et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews2017, Issue 9. Art. No: CD012143. [DOI: 10.1002/14651858.CD012143.pub3]">Jakobsen 2017</a>). These issues could be resolved with the development and application of agreed‐upon sets of outcomes, known as core outcome sets (<a href="http://www.comet-initiative.org" target="_blank">www.comet-initiative.org</a>). The increase in the number of hepato‐biliary randomised trials will never be considered a sufficient valuable source for data if aspects of trial design, such as sample size, completeness of data reporting, duration of follow‐up, and bias risk, are not improved. </p> </section> <section id="CD011564-sec-0116"> <h3 class="title" id="CD011564-sec-0116">Agreements and disagreements with other studies or reviews</h3> <p>Efforts in evaluating the benefits and harms of vitamin D supplementation in people with chronic liver diseases resulted in the absence of evidence or potentially neutral results. It is likely that vitamin D deficiency is not a pathogenetic mechanism contributing to liver damage. There is also the possibility that vitamin D deficiency is the consequence but not the cause of chronic liver diseases. Inflammatory processes involved in the pathogenesis of chronic liver diseases, as well as other chronic diseases, reduce serum vitamin D levels, which can explain their low vitamin D status (<a href="./references#CD011564-bbs2-0054" title="AutierP , BoniolM , MullieP . Vitamin D status and ill health: a systematic review. Lancet Diabetes &amp; Endocrinology2014;2(1):76-89.">Autier 2014</a>). Lifestyle, race, and genetic variations could also be related to vitamin D status (<a href="./references#CD011564-bbs2-0196" title="SkaabyT , HusemoenLL , ThuesenBH , PisingerC , HannemannA , JørgensenT . Longitudinal associations between lifestyle and vitamin D: a general population study with repeated vitamin D measurements. Endocrine2016;51:342-50.">Skaaby 2016</a>). Vitamin D supplementation apparently had no effect on all‐cause mortality, but we are unable to exclude meaningful benefits or harms. This result may be due to the fact that the included randomised clinical trials focused on a group of people with well‐compensated liver diseases at low risk of mortality. </p> <p>Five trials in the current review included people with liver cirrhosis. Given the very low certainty of the evidence, we could not determine if vitamin D supplementation may decrease mortality in people with liver cirrhosis. This finding is contrary to earlier claims in the literature that vitamin D deficiency was associated with increased mortality in people with advanced cirrhosis (<a href="./references#CD011564-bbs2-0178" title="Putz-BankutiC , PilzS , StojakovicT , ScharnaglH , PieberTR , TraunerM , et al. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver International2012;32(5):845-51.">Putz‐Bankuti 2012</a>; <a href="./references#CD011564-bbs2-0212" title="WangJB , AbnetCC , ChenW , DawseySM , FanJH , YinLY , et al. Association between serum 25(OH) vitamin D, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. British Journal of Cancer2013;109(7):1997-2004.">Wang 2013</a>; <a href="./references#CD011564-bbs2-0199" title="StokesCS , KrawczykM , ReichelC , LammertF , GrünhageF . Vitamin D deficiency is associated with mortality in patients with advanced liver cirrhosis. European Journal of Clinical Investigation2014;44(2):176-83.">Stokes 2014</a>; <a href="./references#CD011564-bbs2-0092" title="FinkelmeierF , KronenbergerB , ZeuzemS , PiiperA , WaidmannO . Low 25-hydroxyvitamin D levels are associated with infections and mortality in patients with cirrhosis. PLOS ONE2015;10(6):e0132119.">Finkelmeier 2015</a>; <a href="./references#CD011564-bbs2-0175" title="PaternostroR , WagnerD , ReibergerT , MandorferM , SchwarzerR , FerlitschM , et al. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. Wiener Klinische Wochenschrift2017;129(1-2):8-15.">Paternostro 2017</a>). It seems that vitamin D status in people with liver cirrhosis is not only related to liver dysfunction (<a href="./references#CD011564-bbs2-0155" title="LimLY , ChalasaniN . Vitamin D deficiency in patients with chronic liver disease and cirrhosis. Current Gastroenterology Reports2012;14(1):67-73.">Lim 2012</a>). In earlier years, it was thought that people with cholestatic liver disease were more likely to be vitamin D deficient. Today, it is evident that people with liver cirrhosis, non‐alcoholic fatty liver disease, and chronic hepatitis C are also at risk for low vitamin D levels. Vitamin D deficiency in the last group of people is likely to be multifactorial in aetiology including decreased intake and absorption, altered activity of hepatic 25‐hydroxylase, and insufficient exposure to sunlight (<a href="./references#CD011564-bbs2-0155" title="LimLY , ChalasaniN . Vitamin D deficiency in patients with chronic liver disease and cirrhosis. Current Gastroenterology Reports2012;14(1):67-73.">Lim 2012</a>). Trials including people with liver cirrhosis reported data on biochemical indices after vitamin D supplementation. There seemed to be no significant differences between supplemented and control groups in most of the recorded values, but again we cannot be sure. </p> <p>Our review did not confirm implications that vitamin D supplementation can be beneficial as an adjuvant to other drugs such as interferon or ribavirin (<a href="./references#CD011564-bbs2-0161" title="LuongKV , NguyenLT . Theoretical basis of a beneficial role for vitamin D in viral hepatitis. World Journal of Gastroenterology2012;18(38):5338-50.">Luong 2012</a>). Meta‐analysis of 10 trials that included participants with chronic hepatitis C suggests that vitamin D may benefit rapid, early, and sustained virological response, but our findings are very uncertain. One study suggested noffect of vitamin D supplementation in people with advanced chronic hepatitis C (<a href="./references#CD011564-bbs2-0079" title="CoreyKE , ZhengH , Mendez-NavarroJ , Delgado-BorregoA , DienstagJL , ChungRT , et al. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLOS ONE2012;7(2):e27144.">Corey 2012</a>). Oliveira and colleagues observed no association between vitamin D and the degree of liver fibrosis in people with chronic hepatitis C (<a href="./references#CD011564-bbs2-0174" title="OliveiraKD , BussC , TovoCV . Is there an association between vitamin D and liver fibrosis in patients with chronic hepatitis C. Arquivos de Gastroenterologia2017;54(1):57-9.">Oliveira 2017</a>). Our results are contrary to the result of a meta‐analysis that found a positive relationship between high vitamin D status and sustained virological response in people with hepatitis C virus infection (<a href="./references#CD011564-bbs2-0211" title="VillarLM , Del CampoJA , RanchalI , LampeE , Romero-GomezM . Association between vitamin D and hepatitis C virus infection: a meta-analysis. World Journal of Gastroenterology2013;19(35):5917-24.">Villar 2013</a>). Another meta‐analysis observed that additional use of vitamin D has a positive effect on sustained virological response of people with chronic hepatitis C (<a href="./references#CD011564-bbs2-0144" title="Kim H-B, Myung S-K, Lee Y-J, Park B-J. Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials. Journal of Human Nutrition and Dietetics2018;31(2):168-77.">Kim 2018</a>). A further meta‐analysis, by Kitson and colleagues, found that baseline vitamin D status was not associated with sustained virological response in people with chronic hepatitis C (<a href="./references#CD011564-bbs2-0146" title="KitsonMT , SarrazinC , ToniuttoP , EslickGD , RobertsSK . Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. Journal of Hepatology2014;61(6):1247-52.">Kitson 2014</a>). However, because of paucity of data, we warn that our results may be deeply influenced by systematic and random errors. We found no randomised trials that tested vitamin D supplementation in people with chronic hepatitis B. Farnik and colleagues found that low vitamin D levels were associated with increased hepatitis B virus replication in people with chronic hepatitis B (<a href="./references#CD011564-bbs2-0090" title="FarnikH , BojungaJ , BergerA , AllwinnR , WaidmannO , KronenbergerB , et al. Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology (Baltimore, Md.)2013;58(4):1270-6.">Farnik 2013</a>), whilst Mahamid and colleagues showed a correlation between normal vitamin D levels and spontaneous hepatitis B surface antigen clearance from serum (<a href="./references#CD011564-bbs2-0165" title="MahamidM , NseirW , Abu ElhijaO , ShteingartS , MahamidA , SmamraM , et al. Normal vitamin D levels are associated with spontaneous hepatitis B surface antigen seroclearance. World Journal of Gastroenterology2013;5(6):328-31.">Mahamid 2013</a>). Hoan and colleagues observed vitamin D deficiency in the majority of hepatitis B‐infected people (<a href="./references#CD011564-bbs2-0128" title="HoanNX , KhuyenN , BinhMT , GiangDP , Van TongH , HoanPQ , et al. Association of vitamin D deficiency with hepatitis B virus-related liver diseases. BMC Infectious Diseases2016;16(1):507.">Hoan 2016</a>). A recently published systematic review and meta‐analysis found that vitamin D levels were lower in people with chronic hepatitis B than in healthy controls (<a href="./references#CD011564-bbs2-0133" title="Hu Y-C, Wang W-W, Jiang W-Y, Li C-Q, Guo J-C, Xun Y-H. Low vitamin D levels are associated with high viral loads in patients with chronic hepatitis B: a systematic review and meta-analysis. BMC Gastroenterology2019;19(1):84.">Hu 2019</a>). However, whether vitamin D deficiency is the cause or a consequence of chronic hepatitis is still unknown (<a href="./references#CD011564-bbs2-0061" title="BitettoD , FabrisC , FalletiE , ToniuttoP . Vitamin D deficiency and HCV chronic infection: what comes first. Journal of Hepatology2011;55(4):944-5.">Bitetto 2011</a>). We cannot judge if or to what extent the results reached in the mentioned publications are reliable or not, as we have not evaluated them methodologically. </p> <p>Non‐alcoholic fatty liver disease has become the most common form of chronic liver disease in high‐income countries (<a href="./references#CD011564-bbs2-0186" title="SayinerM , KoenigA , HenryL , YounossiZM . Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clinics in Liver Disease2016;20(2):205-14.">Sayiner 2016</a>; <a href="./references#CD011564-bbs2-0220" title="YounossiZM , KoenigAB , AbdelatifD , FazelY , HenryL , WymerM . Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md.)2016;64(1):73-84.">Younossi 2016</a>). There is a growing interest in exploring the relationship between vitamin D deficiency and severity of non‐alcoholic fatty liver disease. Eleven trials included in our review administered vitamin D to participants with non‐alcoholic fatty liver disease. We were unable to extract data on clinically important outcomes from these trials. We found no significant effect of vitamin D on surrogate outcomes such as liver function tests. Our results are in accordance with the results of three recent meta‐analyses (<a href="./references#CD011564-bbs2-0202" title="TabriziR , MoosazadehM , LankaraniKB , AkbariM , HeydariST , KolahdoozF , et al. The effects of vitamin D supplementation on metabolic profiles and liver function in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Diabetes &amp; Metabolic Syndrome2017;11:S975-82.">Tabrizi 2017</a>; <a href="./references#CD011564-bbs2-0168" title="Mansour-GhanaeiF , PourmasoumiM , HadiA , Ramezani-JolfaieN , JoukarF . The efficacy of vitamin D supplementation against nonalcoholic fatty liver disease: a meta-analysis. Journal of Dietary Supplements2019;17(4):467-85.">Mansour‐Ghanaei 2019</a>; <a href="./references#CD011564-bbs2-0105" title="GuoXF , WangC , YangT , LiS , LiKL , LiD . Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Food and Function2020;11(9):7389-99.">Guo 2020</a>), which also found no significant effect of vitamin D supplementation on biochemical indices in people with non‐alcoholic fatty liver disease. Two meta‐analyses of case‐control and cross‐sectional studies found that people with non‐alcoholic fatty liver disease were more likely to be vitamin D deficient than people in the control groups, suggesting that vitamin D may play a role in the development of non‐alcoholic fatty liver disease (<a href="./references#CD011564-bbs2-0088" title="EliadesM , SpyrouE , AgrawalN , LazoM , BrancatiFL , PotterJJ , et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Alimentary Pharmacology &amp; Therapeutics2013;38(3):246-54.">Eliades 2013</a>; <a href="./references#CD011564-bbs2-0213" title="WangX , LiW , ZhangY , YangY , QinG . Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis. International Journal of Clinical and Experimental Medicine2015;8(10):17221-34.">Wang 2015</a>). A recent systematic review of six randomised clinical trials observed improved lipid profile and inflammatory mediators after vitamin D supplementation (<a href="./references#CD011564-bbs2-0121" title="HaririM , ZohdiS . Effect of vitamin D on non-alcoholic fatty liver disease: a systematic review of randomized controlled clinical trials. International Journal of Preventive Medicine2019;10(1):14.">Hariri 2019</a>). A systematic review and meta‐analysis of observational studies showed that vitamin D status may not be associated with non‐alcoholic fatty liver disease histologic severity (<a href="./references#CD011564-bbs2-0140" title="JaruvongvanichV , AhujaW , SanguankeoA , WijarnpreechaK , UpalaS . Vitamin D and histologic severity of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Digestive and Liver Disease2017;49(6):618-22.">Jaruvongvanich 2017</a>). We also found that vitamin D supplementation may not be beneficial in this population. </p> <p>The evidence on the effect of vitamin D supplementation on liver‐related morbidity and health‐related quality of life is still insufficient. </p> <p>Although three included randomised trials analysed the influence of vitamin D supplementation on bone mineral density in people with liver cirrhosis, we were able to use the data from only one trial (<a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a>). One systematic review and meta‐analysis concluded that vitamin D supplementation for osteoporosis prevention in community‐dwelling adults without specific risk factors for vitamin D deficiency seemed to be inappropriate (<a href="./references#CD011564-bbs2-0179" title="ReidIR , BollandMJ , GreyA . Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet2014;383(9912):146-55.">Reid 2014</a>). Another systematic review and meta‐analysis suggested that vitamin D supplementation did not prevent fractures, falls, and increase bone density in adults (<a href="./references#CD011564-bbs2-0068" title="BollandMJ , GreyA , AvenellA . Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes &amp; Endocrinology2018;6(11):847-58.">Bolland 2018</a>). Similarly, another updated systematic evidence review for the US Preventive Service Task Force found no benefit from vitamin D supplementation for the prevention of cancer and cardiovascular disease (<a href="./references#CD011564-bbs2-0093" title="FortmannSP , BurdaBU , SengerCA , LinJS , WhitlockEP . Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine2013;159(12):824-34.">Fortmann 2013</a>). Bolland and colleagues found that vitamin D did not reduce skeletal, vascular, or cancer outcomes (<a href="./references#CD011564-bbs2-0067" title="BollandMJ , GreyA , GambleGD , ReidIR . The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes &amp; Endocrinology2014;2(4):307-20.">Bolland 2014</a>). Recently completed population‐based randomised clinical trials as well as meta‐analyses of randomised clinical trials found no effect of vitamin D supplementation on cancer occurrence and cardiovascular diseases (<a href="./references#CD011564-bbs2-0190" title="ScraggR , StewartAW , WaayerD , LawesCMM , ToopL , SluyterJ , et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study: a randomized clinical trial. JAMA Cardiology2017;2(6):608-16.">Scragg 2017</a>; <a href="./references#CD011564-bbs2-0191" title="ScraggR , KhawKT , ToopL , SluyterJ , LawesCMM , WaayerD , et al. Monthly high-dose vitamin D supplementation and cancer risk: a post hoc analysis of the Vitamin D Assessment randomized clinical trial. JAMA Oncology2018;4(11):e182178.">Scragg 2018</a>; <a href="./references#CD011564-bbs2-0057" title="BarbarawiM , KheiriB , ZayedY , BarbarawiO , DhillonH , SwaidB , et al. Vitamin D supplementation and cardiovascular disease risks in more than 83 000 individuals in 21 randomized clinical trials: a meta-analysis. JAMA Cardiology2019;4(8):765-76.">Barbarawi 2019</a>; <a href="./references#CD011564-bbs2-0142" title="KeumN , LeeDH , GreenwoodDC , MansonJE , GiovannucciE . Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Annals of Oncology2019;30(5):733-43.">Keum 2019</a>; <a href="./references#CD011564-bbs2-0167" title="MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. New England Journal of Medicine2019;380(1):33-44.">Manson 2019</a>; <a href="./references#CD011564-bbs2-0060" title="Bischoff-FerrariHA , VellasB , RizzoliR , KressigRW , Da SilvaJAP , BlauthM , et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA2020;324(18):1855-68.">Bischoff‐Ferrari 2020</a>). Interestingly, evidence from a Cochrane Review, <a href="./references#CD011564-bbs2-0064" title="BjelakovicG , GluudLL , NikolovaD , WhitfieldK , KrsticG , WetterslevJ , et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD007469. [DOI: 10.1002/14651858.CD007469.pub2]">Bjelakovic 2014b</a>, a meta‐analysis, <a href="./references#CD011564-bbs2-0142" title="KeumN , LeeDH , GreenwoodDC , MansonJE , GiovannucciE . Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Annals of Oncology2019;30(5):733-43.">Keum 2019</a>, and a large randomised clinical trial, <a href="./references#CD011564-bbs2-0221" title="ZhangY , FangF , TangJ , JiaL , FengY , XuP , et al. Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ (Clinical Research Ed.)2019;366:l4673.">Zhang 2019</a>, suggest that vitamin D may reduce cancer mortality in the general population. A recent systematic review and meta‐analysis of randomised clinical trials found no association between vitamin D supplementation and mortality in critically ill patients (<a href="./references#CD011564-bbs2-0176" title="PengL , LiL , WangP , ChongW , LiY , ZhaX , et al. Association between vitamin D supplementation and mortality in critically ill patients: a systematic review and meta-analysis of randomized clinical trials. PLOS ONE2020;15(12):e0243768.">Peng 2020</a>). </p> <p>It seems that health claims are again ahead of the evidence. The great enthusiasm for vitamin D as a cure for a myriad of diseases, reinforced by observational studies showing that healthy people have higher vitamin D status, has not been supported by evidence obtained from randomised clinical trials. It is very likely that low vitamin D status is not the cause but rather the consequence of chronic diseases (<a href="./references#CD011564-bbs2-0102" title="GreyA , BollandM . Vitamin D: a place in the sun. Archives of Internal Medicine2010;170(13):1099-100.">Grey 2010</a>; <a href="./references#CD011564-bbs2-0103" title="GuallarE , Miller ER 3rd, OrdovasJM , StrangesS . Vitamin D supplementation in the age of lost innocence. Annals of Internal Medicine2010;152(5):327-9.">Guallar 2010</a>; <a href="./references#CD011564-bbs2-0122" title="HarveyNC , CooperC . Vitamin D: some perspective please. BMJ (Clinical Research Ed.)2012;345:e4695. [DOI: 10.1136/bmj.e4695]">Harvey 2012</a>; <a href="./references#CD011564-bbs2-0150" title="KupferschmidtK . Uncertain verdict as vitamin D goes on trial. Science2012;337(6101):1476-8.">Kupferschmidt 2012</a>; <a href="./references#CD011564-bbs2-0054" title="AutierP , BoniolM , MullieP . Vitamin D status and ill health: a systematic review. Lancet Diabetes &amp; Endocrinology2014;2(1):76-89.">Autier 2014</a>). We now have some evidence that vitamin D status is a biomarker of health status (<a href="./references#CD011564-bbs2-0196" title="SkaabyT , HusemoenLL , ThuesenBH , PisingerC , HannemannA , JørgensenT . Longitudinal associations between lifestyle and vitamin D: a general population study with repeated vitamin D measurements. Endocrine2016;51:342-50.">Skaaby 2016</a>). It is likely that less healthy people are obese, less active, and more sunlight‐deprived than healthier people, and therefore have lower vitamin D status (<a href="./references#CD011564-bbs2-0159" title="LucasJA , BollandMJ , GreyAB , AmesRW , MasonBH , HorneAM , et al. Determinants of vitamin D status in older women living in a subtropical climate. Osteoporosis International2005;16(12):1641-8.">Lucas 2005</a>; <a href="./references#CD011564-bbs2-0066" title="BollandMJ , GreyAB , AmesRW , MasonBH , HorneAM , GambleGD , et al. Determinants of vitamin D status in older men living in a subtropical climate. Osteoporosis International2006;17(12):1742-8.">Bolland 2006</a>; <a href="./references#CD011564-bbs2-0102" title="GreyA , BollandM . Vitamin D: a place in the sun. Archives of Internal Medicine2010;170(13):1099-100.">Grey 2010</a>; <a href="./references#CD011564-bbs2-0055" title="AutierP . Vitamin D status as a synthetic biomarker of health status. Endocrine2016;51(2):201-2.">Autier 2016</a>; <a href="./references#CD011564-bbs2-0196" title="SkaabyT , HusemoenLL , ThuesenBH , PisingerC , HannemannA , JørgensenT . Longitudinal associations between lifestyle and vitamin D: a general population study with repeated vitamin D measurements. Endocrine2016;51:342-50.">Skaaby 2016</a>). It seems that the cautionary tale of antioxidant supplements is reiterated (<a href="./references#CD011564-bbs2-0095" title="GarattiniS , JakobsenJC , WetterslevJ , BerteléV , BanziR , RathA , et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13-21.">Garattini 2016</a>). The current evidence still does not support the use of vitamin D supplementation to prevent or cure chronic liver diseases. Results of ongoing randomised clinical trials may help us further in resolving the vitamin D enigma. The current evidence suggests that it is prudent to get vitamin D from sun exposure and a balanced diet. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011564-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011564-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011564-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011564-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-FIG-04" target="_blank"><b></b></a></p> </div><img alt="All‐cause mortality.Trial Sequential Analysis was performed based on a mortality in the control group of 2%, a relative risk reduction of 20% in the experimental intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). There was no diversity. The required information size was 63,116 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundary for benefit or harm after the 27th trial. The trial sequential monitoring boundaries were ignored due to little information (3.14%). The blue line represents the cumulative Z‐score of the meta‐analysis. The green dotted lines represent the conventional statistical boundaries." data-id="CD011564-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>All‐cause mortality.</p> <p>Trial Sequential Analysis was performed based on a mortality in the control group of 2%, a relative risk reduction of 20% in the experimental intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). There was no diversity. The required information size was 63,116 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundary for benefit or harm after the 27th trial. The trial sequential monitoring boundaries were ignored due to little information (3.14%). The blue line represents the cumulative Z‐score of the meta‐analysis. The green dotted lines represent the conventional statistical boundaries. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Rapid virological response.Trial Sequential Analysis was performed based on a failure of rapid virological response in the control group of 53%, a relative risk reduction (RRR) of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). There was no diversity. The required information size was 1269 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit but did not cross the trial sequential monitoring boundary for benefit (red down‐sloping line). The blue line represents the cumulative Z‐score of the meta‐analysis. The green dotted lines represent the conventional statistical boundaries. The red inward‐sloping lines represent the trial sequential monitoring boundaries." data-id="CD011564-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Rapid virological response.</p> <p>Trial Sequential Analysis was performed based on a failure of rapid virological response in the control group of 53%, a relative risk reduction (RRR) of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). There was no diversity. The required information size was 1269 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit but did not cross the trial sequential monitoring boundary for benefit (red down‐sloping line). The blue line represents the cumulative Z‐score of the meta‐analysis. The green dotted lines represent the conventional statistical boundaries. The red inward‐sloping lines represent the trial sequential monitoring boundaries. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Early virological response.Trial Sequential Analysis was performed based on failure of early virological response in the control group of 34%, a relative risk reduction of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). The diversity was 88%. The required information size was 21,306 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit. The trial sequential monitoring boundary was ignored due to little information (1.48%). The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries." data-id="CD011564-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Early virological response.</p> <p>Trial Sequential Analysis was performed based on failure of early virological response in the control group of 34%, a relative risk reduction of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). The diversity was 88%. The required information size was 21,306 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit. The trial sequential monitoring boundary was ignored due to little information (1.48%). The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Sustained virological response.Trial Sequential Analysis was performed based on failure of sustained virological response in the control group of 48%, a relative risk reduction (RRR) of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). Diversity was 80%. The required information size was 7570 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit. However, it did not cross any of the monitoring boundaries for benefit, harm, or futility. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries. The red inward‐sloping lines represent the trial sequential monitoring boundaries for benefit and harm." data-id="CD011564-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Sustained virological response.</p> <p>Trial Sequential Analysis was performed based on failure of sustained virological response in the control group of 48%, a relative risk reduction (RRR) of 20% in the intervention group, a type I error of 1.25%, and a type II error of 10% (90% power). Diversity was 80%. The required information size was 7570 participants. The cumulative Z‐curve (blue line) crossed the conventional monitoring boundary for benefit. However, it did not cross any of the monitoring boundaries for benefit, harm, or futility. The blue line represents the cumulative Z‐score of the meta‐analysis. The green lines represent the conventional statistical boundaries. The red inward‐sloping lines represent the trial sequential monitoring boundaries for benefit and harm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 1: 1.1 All‐cause mortality" data-id="CD011564-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 1: 1.1 All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 2: 1.1 All‐cause mortality according to vested interest" data-id="CD011564-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 2: 1.1 All‐cause mortality according to vested interest </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 3: All‐cause mortality according to vitamin D status at entry" data-id="CD011564-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 3: All‐cause mortality according to vitamin D status at entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 4: All‐cause mortality according to form of vitamin D" data-id="CD011564-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 4: All‐cause mortality according to form of vitamin D </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 5: All‐cause mortality (best‐worst‐case and worst‐best‐case scenarios)" data-id="CD011564-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 5: All‐cause mortality (best‐worst‐case and worst‐best‐case scenarios) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 6: Liver‐related mortality" data-id="CD011564-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 6: Liver‐related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 7: Serious adverse events" data-id="CD011564-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 7: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 8: Liver‐related morbidity" data-id="CD011564-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 8: Liver‐related morbidity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 9: Health‐related quality of life" data-id="CD011564-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 9: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 10: Non‐serious adverse events" data-id="CD011564-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 10: Non‐serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 11: Failure of rapid virological response" data-id="CD011564-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 11: Failure of rapid virological response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 12: Failure of early virological response" data-id="CD011564-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 12: Failure of early virological response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 13: Failure of sustained virological response" data-id="CD011564-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 13: Failure of sustained virological response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 14: Acute cellular rejection in liver transplant recipients" data-id="CD011564-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 14: Acute cellular rejection in liver transplant recipients </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 15: Vitamin D status (ng/mL)" data-id="CD011564-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 15: Vitamin D status (ng/mL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 16: Bone mineral density (g/cm)" data-id="CD011564-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 16: Bone mineral density (g/cm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 17: Aspartate aminotransferase (IU/L)" data-id="CD011564-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 17: Aspartate aminotransferase (IU/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 18: Alanine aminotransferase (IU/L" data-id="CD011564-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 18: Alanine aminotransferase (IU/L </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 19: Alkaline phosphatases (IU/L)" data-id="CD011564-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 19: Alkaline phosphatases (IU/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 20: Gamma‐glutamyl transpeptidase (IU/L)" data-id="CD011564-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 20: Gamma‐glutamyl transpeptidase (IU/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 21: Bilirubin (mg/dL)" data-id="CD011564-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 21: Bilirubin (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 22: Triglyceride (mg/dL)" data-id="CD011564-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 22: Triglyceride (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 23: Cholesterol (mg/dL)" data-id="CD011564-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 23: Cholesterol (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 24: LDL cholesterol (mg/dL)" data-id="CD011564-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 24: LDL cholesterol (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 25: Albumin (g/L)" data-id="CD011564-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 25: Albumin (g/L)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 26: HDL cholesterol (mg/dL)" data-id="CD011564-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 26: HDL cholesterol (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 27: Calcium (mg/dL)" data-id="CD011564-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 27: Calcium (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 28: Glucose (mg/dL)" data-id="CD011564-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 28: Glucose (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 29: Phosphorus (mg/dL)" data-id="CD011564-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 29: Phosphorus (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 30: Adiponectin (µg/mL)" data-id="CD011564-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 30: Adiponectin (µg/mL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 31: Insulin (mIU/mL)" data-id="CD011564-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 31: Insulin (mIU/mL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 32: Parathyroid hormone (pg/mL)" data-id="CD011564-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 32: Parathyroid hormone (pg/mL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011564-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/urn:x-wiley:14651858:media:CD011564:CD011564-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D versus placebo or no intervention, Outcome 33: C‐reactive protein (mg/L)" data-id="CD011564-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_t/tCD011564-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D versus placebo or no intervention, Outcome 33: C‐reactive protein (mg/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/media/CDSR/CD011564/image_n/nCD011564-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011564-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vitamin D compared with placebo or no intervention for chronic liver diseases in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vitamin D compared with placebo or no intervention for chronic liver diseases in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic liver diseases<br/><b>Setting:</b> in‐ and outpatients<br/><b>Intervention:</b> vitamin D<br/><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vitamin D</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Follow‐up: mean 7 months (1 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.51 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1979<br/>(27 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/>(11 to 30) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Liver‐related mortality</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.62<br/>(0.08 to 34.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>18<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No information was available to calculate absolute effects.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> <p>Follow‐up: mean 10.5 months (6 to 12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Several serious adverse events were reported: hypercalcaemia (RR 5.00, 95% CI 0.25 to 100.8; 1 trial; 76 participants); myocardial infarction (RR 0.75, 95% CI 0.08 to 6.81; 2 trials; 86 participants); thyroiditis (RR 0.33, 95% CI 0.01 to 7.91; 1 trial; 68 participants); circular haemorrhoidal prolapse (RR 3.00, 95% CI 0.14 to 65.9; 1 trial; 20 participants); bronchopneumonia (RR 0.33, 95% CI 0.02 to 7.32; 1 trial; 20 participants). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Liver‐related morbidity</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Health‐related quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐serious adverse events</p> <p>Follow‐up: mean 7 months (3 to 12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 trial reported 1 single non‐serious adverse event, and another trial reported 16 single non‐serious adverse events, for a total of 17 types of non‐serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure of sustained virological response</p> <p>Follow‐up: mean 16 months (6 to 18 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.65<br/>(0.42 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>630<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>484 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>315 per 1000<br/>(203 to 489) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded because of risk of bias (1 level) (all trials were at high risk of bias); and imprecision (2 levels) (few events, and the optimal information size of 63,116 participants (based on a proportion of 2% in the control group, a relative risk reduction of 20%, an alpha of 1.25%, and a beta of 10%) was not met; wide CI which included both benefits and harms).<br/><sup>2</sup>Downgraded because of risk of bias (1 level) (the trial was at high risk of bias); and imprecision (2 levels) (very few events, and wide CI which included both benefits and harms).<br/><sup>3</sup>Downgraded because of risk of bias (1 level) (all trials were at high risk of bias); and imprecision (2 levels) (very few events, and wide CI which included both benefits and harms).<br/><sup>4</sup>Downgraded because of risk of bias (1 level) (all trials were at high risk of bias); imprecision (2 levels) (the optimal information size of 7570 participants (based on a proportion of 48% in the control group, a relative risk reduction of 20%, an alpha of 1.25%, and a beta of 10%) was not met); inconsistency (1 level) (considerable heterogeneity); and indirectness (3 levels)(sustained virological response is a surrogate outcome). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vitamin D compared with placebo or no intervention for chronic liver diseases in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011564-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included trials (I)</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Protocol</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Groups</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias<br/>risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Blinding</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants<br/>(n)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Women<br/>(%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean<br/>age (years)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parallel group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>n: number of participants<br/>NI: no intervention<br/>PL: placebo </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included trials (I)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011564-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included trials (II)</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome measures</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sponsor</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Country</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Israel</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver steatosis, liver function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1, 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical indices, HOMA, FibroScan measurement</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical indices</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver steatosis, liver function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD (NASH)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver steatosis, liver function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Switzerland</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum 25‐hydroxyvitamin D, adiponectin, HOMA‐IR, liver enzymes, and change in grade of NAFLD </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body weight, BMI, insulin resistance, dyslipidaemia, hepatic enzymes, CRP, and adiponectin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pakistan</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1, 2, 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Republic of Korea</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver cirrhosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum levels of T‐helper cells associated cytokines</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum fibrotic markers</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver function, body fat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver cirrhosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 2 or 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Israel</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver cirrhosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D status, liver function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insulin resistance and serum ALT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver function, insulin resistance index</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver cirrhosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary biliary cirrhosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NAFLD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical indices, liver steatosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1, 2, 3, 4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver transplant recipients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute cellular rejection rate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatitis C genotype 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sustained virological response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ALT: alanine aminotransferase<br/>BMI: body mass index<br/>CRP: C‐reactive protein<br/>HOMA‐IR: homeostatic model assessment for insulin resistance<br/>NAFLD: non‐alcoholic fatty liver disease<br/>NASH: non‐alcoholic steatohepatitis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included trials (II)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011564-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included studies (III)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Vitamin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Calcium</b> <br/>(<b>mg)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Regimen</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Treatment<br/>(weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Follow‐up<br/>(weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Co‐intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>D<sub>3</sub> </b> <br/>(<b>IU)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>D<sub>2</sub> </b> <br/>(<b>IU)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>25(OH)D</b> <br/>(IU<b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1,25(OH)<sub>2</sub>D</b> <br/>(<b>µg)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0001" title="Abu-MouchS , FiremanZ , JarchovskyJ , ZeinaAR , AssyN . Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology2011;17(47):5184-90. ">Abu‐Mouch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0002" title="AtsukawaM , TsubotaA , ShimadaN , YoshizawaK , AbeH , AsanoT , et al. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatology Research2016;46(5):450-8. ">Atsukawa 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV, SP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0003" title="BarchettaI , Del BenM , AngelicoF , Di MartinoM , FraioliA , La TorreG , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine2016;14:92. ">Barchetta 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0004" title="BeheraMK , ShuklaSK , DixitVK , NathP , AbhilashVB , AsatiPK , et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian Journal of Medical Research2018;148(2):200-6. ">Behera 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0005" title="BoonyagardS , TechatuvananK . Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients. Hepatology (Baltimore, Md.)2016;64(S1):542. ">Boonyagard 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0006" title="DabbaghmaneshMH , DanafarF , EshraghianA , OmraniGR . Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes and Metabolic Syndrome2018;12(4):513-7. ">Dabbaghmanesh 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly and daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0007" title="EsmatG , El RazikyM , ElsharkawyA , SabryD , HassanyM , AhmedA , et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon &amp; Cytokine Research2015;35(1):49-54. ">Esmat 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0008" title="ForoughiM , MaghsoudiZ , AskariG . The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iranian Journal of Nursing and Midwifery Research2016;21(1):100-4. ForoughiM , MaghsoudiZ , GhiasvandR , IrajB , AskariG . Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. International Journal of Preventive Medicine2014;5(8):969-75. ">Foroughi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0009" title="GeierA , EichingerM , StirnimannG , SemelaD , TayF , SeifertB , et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology2018;53(9):1114-20. ">Geier 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0010" title="HosseiniSM , AliashrafiS , Ebrahimi-MameghaniM . The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial. Iranian Red Crescent Medical Journal2018;20(10):1-12. ">Hosseini 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intramuscularly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E 400 IU/day</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0011" title="HussainM , IqbalJ , MalikSA , WaheedA , ShabnumS , AkhtarL , et al. Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients. Pakistan Journal of Pharmaceutical Sciences2019;32(3 Special):1343-8. ">Hussain 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0012" title="JeongJY , JunDW , ParkSJ , SohnJH , KimSG , LeeSW , et al. Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. Korean Journal of Internal Medicine2019;35(5):1074-83. ">Jeong 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24, 48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48, 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0013" title="JhaAK , JhaSK , KumarA , DayalVM , JhaSK . Effect of replenishment of vitamin D on survival in patients with decompensated liver cirrhosis: a prospective study. World Journal of Gastrointestinal Pathophysiology2017;8(3):133-41. ">Jha 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300,000; 800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intramuscularly and orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose; daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0014" title="KomolmitP , CharoensukK , ThanapiromK , SuksawatamnuayS , ThaimaiP , ChirathawornC , et al. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLOS ONE2017;12(4):e0174608. ">Komolmit 2017a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60,000; 80,000; 100,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0015" title="KomolmitP , KimtrakoolS , SuksawatamnuayS , ThanapiromK , ChattrasophonK , ThaimaiP , et al. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Scientific Reports2017;7(1):8905. ">Komolmit 2017b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60,000; 80,000; 100,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0016" title="Lorvand AmiriH , AgahS , MousaviSN , HosseiniAF , ShidfarF . Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Archives of Iranian Medicine2016;19(9):631-8. Lorvand AmiriH , AgahS , Tolouei AzarJ , HosseiniS , ShidfarF , MousaviSN . Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial. Clinical Nutrition2016;16:31260-2. ShidfarF , MousaviSN , Lorvand AmiriH , AgahS , HoseiniS , HajimiresmailSJ . Reduction of some atherogenic indices in patients with non-alcoholic fatty liver by vitamin D and calcium co-supplementation: a double blind randomized controlled clinical trial. Iranian Journal of Pharmaceutical Research2019;18(1):496-505. ">Lorvand Amiri 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0017" title="MobarhanSA , RussellRM , ReckerRR , PosnerDB , IberFL , MillerP . Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology (Baltimore, Md.)1984;4(2):266-73. ">Mobarhan 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0018" title="NimerA , MouchA . Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology2012;18(8):800-5. ">Nimer 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0019" title="PilzS , Putz-BankutiC , GakschM , SpindelboeckW , HaselbergerM , RainerF , et al. Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients2016;8(5):278. ">Pilz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0020" title="SakpalM , SatsangiS , MehtaM , DusejaA , BhadadaS , DasA , et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Journal of Gastroenterology and Hepatology Open2017;1(2):62-7. ">Sakpal 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intramuscularly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0021" title="SharifiN , AmaniR , HajianiE , CheraghianB . Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine2014;47(1):70-80. SharifiN , AmaniR , HajianiE , CheraghianB . Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Experimental Biology &amp; Medicine (Maywood)2016;241(8):830-8. ">Sharifi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice a week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0022" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone disease in patients with cirrhosis of the liver. Journal of Gastroenterology and Hepatology1999;14(6):547-52. ">Shiomi 1999a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0023" title="ShiomiS , MasakiK , HabuD , TakedaT , NishiguchiS , KurokiT , et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. Journal of Gastroenterology1999;34(2):241-5. ">Shiomi 1999b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0024" title="TaghvaeiT , AkhaO , MouodiM , FakheriHT , KashiZ , MalekiI , et al. Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Medica Mediterranea2018;34:415–22. ">Taghvaei 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lifestyle modification</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0025" title="VosoghiniaH , EsmaeilzadehA , GanjiA , HosseiniSM , JamehdarSA , SalehiM , et al. Vitamin D in standard HCV regimen (PEG-Interferon plus Ribavirin), its effect on the early virologic response rate: a clinical trial. Razavi International Journal of Medicine2016;4(2):e36632. ">Vosoghinia 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0026" title="XingT , QiuG , ZhongL , LingL , HuangL , PengZ . Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Pharmazie2013;68(10):821-6. ">Xing 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011564-bbs2-0027" title="YokoyamaS , TakahashiS , KawakamiY , HayesCN , KohnoH , KohnoH , et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis2014;21(5):348-56. ">Yokoyama 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEG‐IFN, RBV</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>1,25(OH)<sub>2</sub>D: calcitriol<br/>25(OH)D: calcidiol<br/>IU: international unit<br/>PEG‐IFN: pegylated‐interferon<br/>RBV: ribavirin<br/>SP: simeprevir </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included studies (III)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/full#CD011564-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011564-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin D versus placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.51, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Non‐alcoholic fatty liver disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Chronic hepatitis C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Liver cirrhosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.53, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Liver transplant recipients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 1.1 All‐cause mortality according to vested interest <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.51, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Trials with vested interest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [0.15, 48.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Trials without vested interest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.48, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality according to vitamin D status at entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.51, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Normal vitamin D status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Low vitamin D status</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.53, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause mortality according to form of vitamin D <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Vitamin D 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.48, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Vitamin D 2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.15, 61.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 1,25‐dihydroxyvitamin D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 25‐hydroxyvitamin D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.15, 61.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All‐cause mortality (best‐worst‐case and worst‐best‐case scenarios) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Best‐worst‐case scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.06, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Worst‐best‐case scenario</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.95 [3.55, 17.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Liver‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.08, 34.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Hypercalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 100.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.08, 6.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Thyroiditis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Circular haemorrhoidal prolapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.5 Bronchopneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Liver‐related morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Glossitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [0.16, 87.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Lower back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.4 Abdominal bloating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.5 Cold</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.6 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.7 Sore throat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.8 Sour taste in mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.9 Contused lacerated wound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.10 Multiple white matter lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.11 Gastro‐oesophageal reflux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.12 Abdominal menstrual cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.13 Tubular colon adenoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.14 Gastric motility disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.15 Irritable bowel syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.27, 92.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.16 Knee pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.17 Severe allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.09 [0.25, 103.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Failure of rapid virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Failure of early virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.11, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Failure of sustained virological response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.42, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Acute cellular rejection in liver transplant recipients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Vitamin D status (ng/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.49 [14.52, 22.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Bone mineral density (g/cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.04, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Aspartate aminotransferase (IU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.75 [‐5.41, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Alanine aminotransferase (IU/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.30 [‐7.60, 3.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Alkaline phosphatases (IU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.95 [‐15.10, 13.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Gamma‐glutamyl transpeptidase (IU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.69 [‐5.26, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Bilirubin (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.00, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Triglyceride (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.27 [‐10.99, 33.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.51 [‐2.83, 9.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 LDL cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐8.70, 6.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Albumin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.18 [‐2.96, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 HDL cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [‐0.64, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Calcium (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.12, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Glucose (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [‐5.05, 7.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Phosphorus (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.16, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Adiponectin (µg/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [‐0.27, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Insulin (mIU/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐1.15, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Parathyroid hormone (pg/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.18 [‐38.54, 8.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 C‐reactive protein (mg/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.93, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin D versus placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011564.pub3/references#CD011564-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011564.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011564-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011564-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011564-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011564-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011564-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD011564-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD011564-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011564-note-0019">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD011564-note-0009">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD011564-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD011564-note-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011564-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011564-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011564\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011564\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011564\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011564\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011564\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011564.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011564.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011564.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011564.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011564.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716546868"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011564.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716546872"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011564.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da22808119379',t:'MTc0MDcxNjU0Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 